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Abstract
Aptamers are in vitro selected oligonucleotides (DNA, RNA, oligos with modi-
fied nucleotides) that can have high affinity and specificity for a broad range 
of potential targets with high affinity and specificity. Here we focus on their 
applications as biosensors in the diagnostic field, although they can also be used as 
therapeutic agents. A small number of peptide aptamers have also been identified. 
In analytical settings, aptamers have the potential to extend the limit of current 
techniques as they offer many advantages over antibodies and can be used for 
real-time biomarker detection, cancer clinical testing, and detection of infectious 
microorganisms and viruses. Once optimized and validated, aptasensor technolo-
gies are expected to be highly beneficial to clinicians by providing a larger range and 
more rapid output of diagnostic readings than current technologies and support 
personalized medicine and faster implementation of optimal treatments.
Keywords: aptamer, SELEX, biosensors, aptasensors, diagnostics, infectious diseases
1. Introduction
In 1868, a young Swiss physician Friedrich Miescher isolated a new biological com-
pound from nuclei of white blood cells, which had not been described before. He named 
it “nuclein” [1]. Today, it is known as “deoxyribonucleic acid (DNA)” which is nucleic 
acid in nature and carries heritable information for biological organisms. However, with 
advancements in the molecular genetics field, scientists started to discover new functions 
of nucleic acids other than storing and transferring genetic information [2].
In the 1980s, research on human immunodeficiency virus (HIV) and adenoviruses 
revealed a new understanding of the importance of selective interactions between nucleic 
acids and proteins. These studies demonstrated that viruses express small RNAs, which 
bind to cellular or viral proteins with high specificity. In parallel with these discoveries, 
scientists focused on deciphering fundamental features of short RNAs that can fold into 
unique three-dimensional structures [3]. In 1990, three separate groups [4–6] invented 
the systematic evolution of ligands by exponential enrichment (SELEX) method by 
which they obtained nucleic acid molecules, similar to naturally occurring nucleic acids, 
which have high specificities and affinities toward their targets. They named these in vitro 
selected molecules “aptamers.” Since then, researchers have selected numerous aptamers 
against targets varying from small molecules to cells using SELEX [3].
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1.1 Systematic evolution of ligands by exponential enrichment
SELEX is a technique to isolate an aptamer that is specific for the desired target 
from a randomized oligonucleotide (oligo) library by simulating evolution (system-
atic evolution of ligands). This in vitro technique includes a number of selection 
rounds (between 5 and 20) alternated with exponential amplification of the fittest 
oligonucleotides by PCR for DNA libraries or RT-PCR for RNA libraries (exponen-
tial enrichment).
In a typical SELEX experiment, the starting pool contains up to 1015 random 
oligonucleotide sequences. These sequences in the pool have a unique three-dimen-
sional (3D) structures defined by the combination of interactions that include base 
pairing, stacking, sugar packing, and noncanonical intramolecular interactions. 
This structural complexity in the pool establishes a high probability of selecting an 
oligo that can interact avidly and specifically with the target of interest (aptamer). 
The intermolecular interaction between aptamer and target may include hydrogen 
bonds, salt bridges, van der Waals, and hydrophobic and electrostatic interactions.
Traditionally, SELEX is comprised of three main steps: incubation, separa-
tion, and amplification. The process involves incubating a “library” of oligos with 
randomized internal sequences of 20–60 nt with target molecules for a chosen 
period of time. Removal of unbound oligos from this mixture completes this initial 
step. Oligos that remain bound to the target are separated and amplified either 
by PCR or RT-PCR depending on the oligo type, DNA, or RNA. For DNA SELEX, 
biotin-labeled primers can be used in PCR, and the resulting double-stranded 
forms are separated using methods such as streptavidin bead capture. For RNA, 
T7 RNA polymerase promoter-containing primers are used in RT-PCR after which 
RNA libraries are amplified by in vitro transcription. The protocol follows the 
same amplification steps for several rounds (4–20) as for DNA SELEX (Figure 1). 
Negative selection can be included in either RNA or DNA SELEX protocols, which is 
achieved by passing the nucleic acid pool over a supporting matrix in the absence of 
the target. This step aims at eliminating the oligos that bind the matrix in a target-
independent manner. Analogs of the target can also be included during selection 
rounds as competitors of binding if there is a means of separating the target from 
the analog competitors. This competition is expected to result in aptamers with 
higher specificity for the target over the analogs.
Two alternative protocols are followed after these rounds to complete the 
SELEX. The selected oligos from the final round are cloned and sequenced for aptamer 
identification. Alternatively, high-throughput sequencing (or next-generation 
sequencing) can be employed to obtain sequence data from oligos present in the pool 
after different rounds of selection. Comparative sequence analysis allows pinpointing 
Figure 1. 
Schematic representation of SELEX protocol.
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consensus sites that are potentially involved in target recognition [7, 8]. The most 
promising sequences are synthesized and characterized further, among which aptam-
ers with nanomolar dissociation constants are frequently identified. In some instances, 
aptamers have also been isolated with picomolar dissociation constants.
In vitro selection can take months. To shorten the time for selecting high affinity 
aptamers, Golden et al. suggested a new method for SELEX: photochemical SELEX 
(PhotoSELEX) [9]. The technique involves the evolution of modified DNA aptam-
ers, which are capable of forming a photoinduced covalent bond with their targets. 
Thus, these aptamers have greater specificity, and fewer selection rounds are 
required to select aptamers compared with the traditional SELEX methodologies.
1.2 Aptamer structure
Aptamer selection directly depends on environmental components during 
SELEX. This is because the ionic components and pH of the environment can dictate 
the predominant structures of oligos in the pool. Nucleic acids are negatively charged 
molecules that create an “ionic atmosphere” for ion-nucleic acid interactions, a freely 
joined sheath of ions surrounding the nucleic acids. These electrostatic interactions 
directly affect the structure of nucleic acids and thus the target binding by changing 
charge distribution. For specific ligand binding, it is crucial that the aptamer reli-
ably forms the appropriate three-dimensional (3D) structure. However, structures 
of short oligonucleotides like aptamers are affected by the incubation temperature 
and the components of the operating buffer system such as the specific ions, ionic 
strength, and pH. Therefore, the affinities and future performance of aptamers 
depend on the buffers used during aptamer selection, and the choice of buffer pres-
ent during selection requires attention when developing a SELEX protocol [10–13].
Some factors present in the samples to be analyzed may have a negative impact 
on aptamer performance. For example, aptamers are susceptible to nucleases that 
are present in many biological samples. This is particularly true for RNA, having 
the 2'OH group, which can electrophilically attack the phosphate of the nucleic 
acid backbone. Nucleases promote this chemical property to catalyze hydrolysis 
of RNA, and this property also makes RNA more chemically labile to high pH and 
temperature compared with DNA. To counter this susceptibility to hydrolysis and 
to stabilize nucleic acids, many post-selection chemical modifications can be made. 
However, incorporating these modifications into the aptamer after its selection 
carries a large risk of altering the aptamer structure with a resulting loss of affinity 
for the target analyte. Alternatively, the less risky approach is to use chemically 
substituted nucleotide analogs during SELEX.
Secondary motifs in the tertiary structures of aptamers are diverse. Such motifs 
include the “stem-loop,” “hairpin structure,” “pseudoknot,” “internal bulge,” 
“kissing loop,” “three-way junction,” and “the G-quadruplex.” To understand 
these structures in detail, X-ray crystallography or nuclear magnetic resonance 
spectroscopy is utilized. But these techniques are laborious and expensive. To ease 
the process, computer algorithms have been developed to estimate the lowest free-
energy structures using sequence-based modeling [14]. This makes it possible to 
quickly predict the secondary structure of oligonucleotides without needing many 
resources. However, computational approaches to obtaining 3D models of nucleic 
acid structures by modeling from primary sequence are still in the development 
phase, and the results are not as reliable as experimental methods [15–17].
Aptamers have a significant advantage over antibodies as components of sensing 
units. One advantage is that nucleic acid structures can be regenerated several times 
with little activity loss, whereas protein-based antibodies can only be used once or 
a few times before their functionality is lost. In contrast to antibodies or enzymes, 
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nucleic acid aptamers are often highly stable and can be inexpensively synthesized 
with high reproducibility and purity. Like antibodies, they bind their targets with 
high affinity and specificity (Table 1). These properties are motivating the current 
flood of reports of aptamer-based biosensors employing a wide range of technologies.
1.3 Aptamers for diagnostic and therapeutic applications
Development of novel biosensors for various clinical diseases has become 
essential as new health issues emerged. To meet this goal, antibodies have been used 
extensively; however, more recently, aptamers have been recognized as promising 
alternatives for developing diagnostic devices.
A biosensor is a tool with the ability to provide a measurable signal as a result 
of biomolecular interactions. Biosensors generally consist of two components: a 
bioreceptor and a transducer. The bioreceptor binds specifically to the molecule of 
interest, and the transducer turns information from the binding event into a detect-
able signal. The components of the transducer include a detector and a reporter, 
which acts as a bridge between the bioreceptor and the detector.
The most critical part of the biosensor is the bioreceptor (or bio-recognition ele-
ment). The success of the sensor directly depends on its high affinity and specificity. 
Because of their more flexible structures, aptamers can provide a substantial signal in 
combination with a larger number of detection methods than possible for antibodies. 
Aptamers are preferred over antibodies for biosensor applications because of their 
cost, stability, and reusability as well as the aforementioned advantages (see Table 1). 
Biosensors, called “aptasensors,” have been developed with many detectors including 
electrochemical, optical, microcantilever, and acoustic detectors [10].
Aptamers are also used in therapeutic applications, which will not be extensively 
discussed in this chapter. For discussions of therapeutic applications, the reader 
is directed to reviews that focus on this topic [18–21]. The majority of therapeutic 
aptamers inhibit their target molecules, and some act as receptor agonists. Potential 
therapeutic aptamers against proteins including nucleolin, chemokine ligand 12, 
or thrombin have been described. Several RNA and DNA aptamers are undergoing 
clinical trials, yet only pegaptanib against vascular endothelial growth factor has so 
far been in the USA by the FDA for the treatment of vascular ocular disease [3].
To advance therapeutic applications, drug delivery systems with aptamers have 
been developed. For such applications, aptamers are needed that recognize cell sur-
face proteins, which can be challenging to select because these proteins are difficult to 
purify in their natural conformations. The development of cell-based selection tech-
niques has enabled aptamer selection against proteins in their native form while they 
are on the cell surface. These selections are performed against single-cell types [22] 
Table 1. 
Comparison of aptamers with antibodies.
5Aptamers for Diagnostics with Applications for Infectious Diseases
DOI: http://dx.doi.org/10.5772/intechopen.84867
to obtain aptamers with the ability to bind cell surface proteins specifically expressed 
on the surface of the cell type used for selection. Delivery systems with these aptam-
ers can carry a variety of cargos into cells by taking advantage of the surface protein 
internalization in response to aptamer-receptor binding.
2. Aptamer use in diagnostics
Diagnostics is one of the most dynamic fields in biosensor research. To support 
early diagnosis and individualized medicine, researchers seek to develop methods to 
detect identified biomarkers by more sensitive, time-saving, and cheaper methods. 
The perfect sensor for medical diagnostics should also be specific, reusable, easy 
to monitor, nonreactive, and stable with various biological samples. Aptamers can 
be developed to meet all these requirements. With their wide spectrum of possible 
targets, sensitive detection of virtually all toxins, drugs, peptides, proteins, metabo-
lites, biomarkers, and cells is possible with aptamers.
Several types of aptasensors have been developed based on electrochemical, 
optical, mechanical, and acoustic approaches. An early use of aptamers as bio-rec-
ognition elements in aptasensors was reported in 1996 with an optical biosensor that 
utilized fluorescently labeled aptamers in a homogenous assay [23]. Later, aptamers 
were integrated onto solid supports, which provided an opportunity for real-time 
analyte detection. Most of these studies have been at the proof-of-principle level, and 
the majority of studies have been performed with the thrombin aptamer (TA), which 
has the advantage of a stable target and aptamer. Thrombin aptamer self-assembles 
into a highly stable G-quadruplex structure, and thrombin is a structurally stable 
globular protein found in blood. Future studies to optimize other aptasensors with 
less stable aptamers and analytes in complex matrices are likely to be challenging.
Aptamers fold their flexible, single-stranded chains into 3D structures, which 
may change upon binding to their cognate target molecules. This structure-
switching characteristic has been capitalized on in many aptamer applications. 
An early example used electrochemical sensing with aptamers immobilized on an 
electrode surface, and target binding is observed by measuring electrochemical 
current variations. This system utilized an amperometric sandwich assay com-
bining TA on a gold electrode which was used to capture the TA-labeled glucose 
dehydrogenase (GDH) [24].
Several types of aptasensors have been developed based on electrochemical, 
optical, mechanical, and acoustic approaches, which are discussed in the following 
sections.
2.1 Electrochemical aptasensors
Electrochemical aptasensors are constructed by attaching an aptamer that carries a 
redox-active moiety to an electrode surface. Such aptasensors can make use of voltam-
metric (amperometric), potentiometric, conductometric, or impedimetric assays 
for analyte detection. In some formats, the aptamer is labeled with an electroactive 
group and a structural change in the aptamer upon binding to the target analyte and 
changes the distance of the electroactive group from the electrode surface, resulting 
in the switching “on/off” of the electrochemical signal. Measurement of changes 
in electrochemical features after target binding has been used to determine target 
concentration [24]. So far, electrochemical aptasensors have been reported for a wide 
range of targets including PDGF, thrombin and immunoglobulin E (IgE), cocaine, 
theophylline, adenosine, aminoglycosides, and adenosine triphosphate (ATP) and 
inorganic ions such as potassium (K+) [10].
Recent Advances in Analytical Chemistry
6
In addition to their innate structural changes on binding their target molecules, 
other structural constraints can be applied to aptamers that result in signals for 
detection by electrochemical approaches. The most commonly used additional 
constraint is an oligonucleotide (either connected with the aptamer or separate) 
that is complementary to part of the aptamer and, upon hybridizing with the 
aptamer, constrains its structure to an inactive form. For example, a biotin-tagged 
DNA aptamer for zeatin was hybridized with a complimentary “assist DNA” to form 
a Y-type DNA structure. Avidin-modified alkaline phosphatase (ALP) was attached 
to this structure with two biotins at the terminals of DNA aptamer. In the presence 
of zeatin, this complex was disrupted which leads to a decrease in the oxidation 
signal from p-nitrophenol (PNP) produced by the catalytic effect of ALP. From 
this, zeatin concentration in the range of 50 pM–50 nM was selectively measured 
with a detection limit of 16.6 pM [25].
Redox-active methylene blue (MB) has been used as an aptamer label and 
electrotransfer communication agent with the electrode. Methylene blue enables the 
detection of changes in aptamer conformation upon target binding. For example, 
an MB-labeled TA was used to construct an aptasensor by its immobilization on an 
electrode. The flexible conformation of the aptamer enabled the electrotransfer 
from MB to the electrode. The structural change upon analyte binding shielded 
MB in a “signal-off” mode. However, this mode is a disadvantage for diagnostics 
because the amperometric response decreases as a result of the association of the 
target thrombin with the aptamer.
Several approaches have been taken to develop aptasensors that operate in a 
“signal-on” mode. As an example, the TA was modified with an electroactive fer-
rocene group as the redox label at one end and a thiol group at the other end. The 
electrical contact of the electrode with the ferrocene label was affected by the long, 
flexible aptamer chain. Thrombin binding stabilizes the aptamer’s G-quadruplex 
conformation, which brings the ferrocene group closer to the electrode. This close 
proximity enables electron transfer between the electro-active ferrocene units 
and the electrode, thus producing a positive signal in the presence of thrombin. 
A similar approach to creating signal-on electrochemical aptasensors utilized the 
conformational change in the cocaine aptamer that occurs on binding its target. In 
the absence of the target, the aptamer on the solid surface stays in a partially folded 
form as a three-way junction. Cocaine binding decreases the distance for electron 
transfer and thus increases the signal [26].
Demirkol et al. generated an electrochemical aptasensor to detect E. coli 
O157:H7. The electrode surfaces were modified by cysteamine via self-assembled 
monolayer formation. The carboxyl-functionalized quantum dots and aptamers 
were conjugated to cysteamine-modified gold electrodes [27]. Ge et al. reported 
an affinity-mediated homogeneous electrochemical aptasensor using graphene-
modified glassy carbon electrode (GCE) as the sensing platform. In this approach, 
the aptamer-target recognition is converted into an ultrasensitive electrochemical 
signal output with the aid of a novel T7 exonuclease (T7Exo)-assisted target-analog 
recycling amplification strategy, in which ingeniously designed methylene blue 
(MB)-labeled hairpin DNA reporters are digested in the presence of target and, 
then, converted to numerous MB-labeled long ssDNAs. The distinct difference in 
differential pulse voltammetry response between the designed hairpin reporters 
and the generated long ssDNAs on the graphene/GCE allows ultrasensitive detec-
tion of target biomolecules [28]. Lai et al. proposed a renewable electrochemical 
aptasensor for super sensitive Hg2+ determination [29]. The novel aptasensor, 
based on sulfur-nitrogen co-doped ordered mesoporous carbon (SN-OMC) and 
a thymine-Hg2+-thymine (T-Hg2+-T) mismatch structure, used ferrocene as signal 
molecules to achieve the conversion of signal to current. In the absence of Hg2+, 
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the thiol-modified T-rich probe 1 spontaneously formed a hairpin structure by 
base pairing. After hybridizing with the ferrocene-labeled probe 2 in the pres-
ence of Hg2+, the hairpin structure of probe 1 was opened due to the preferential 
formation of the T-Hg2+-T mismatch structure, and the ferrocene signal molecules 
approached the modified electrode surface. Sulfur-nitrogen co-doped ordered 
mesoporous carbon with high specific surface area and ample active sites acted as a 
signal amplification element in electrochemical sensing. The sensitive determina-
tion of Hg2+ can be actualized by analyzing the relationship between the change of 
oxidation current caused by ferrocene and the Hg2+ concentrations [29]. Finally, 
Wang et al. combined the strengths of advanced aptamer technology, DNA-based 
nanostructure, and portable electrochemical devices to develop a nanotetrahedron 
(NTH)-assisted aptasensor for direct capture and detection of hepatocellular 
exosomes. The oriented immobilization of aptamers significantly improved their 
accessibility to suspended exosomes, and the NTH-assisted aptasensor could detect 
exosomes with 100-fold higher sensitivity when compared to the single-stranded 
aptamer-functionalized aptasensor [30].
Recently, nanoporous metal surfaces have been found as good sensor platforms for 
aptamers. Nanoporous gold [31, 32]-based sensors have been used with the TA and 
ATP aptamers and a redox probe to provide the electrons to the gold surface for sensi-
tive detection of analyte by electrochemical impedance spectroscopy (EIS). The ATP 
aptamer was in a split format with the second half of the aptamer covalently linked 
with 3,4-diaminobenzoic acid (DABA), which created the EIS signal by its oxidation at 
the gold interface. For an analyte that can undergo redox reactions, such as bisphenol 
A (BPA), this property can be used to provide a signal [33]. Other nanoporous surfaces 
such as graphene oxide/Au composites and porous PtFe or PtTiAl ternary alloys have 
also been employed to measure breast cancer cells using the MUC-1 aptamer linked 
with the electroactive label thionine [34] or kanamycin with [Fe(CN)6]3−/4− [35]. The 
ability of aptamers to hybridize with other oligonucleotides was employed to create 
molecular gates over the pores in nanoporous gold surfaces. The gate, created with 
an aptamer highly specific for the avian influenza viruses (AIV) H5N1 hybridized to 
oligos linked to the nanoporous gold surface, was closed in the absence of AIV H5N1 
but open when the virus bound and released the aptamer. The open pores allowed the 
entry of substrate and cofactor for lactate dehydrogenase, layered on a glassy electrode 
below the nanoporous gold. Cyclic voltammetry was used to detect the gold-catalyzed 
oxidation of the NADH produced as a result of LDH activity [34].
Nanoporous anodized aluminum oxide surfaces have more recently been used 
for providing a nanoporous surface through which electron movement can be 
controlled by aptamer-analyte binding. In these aptasensors, the aptamers are 
attached to a gold surface, which is provided by 2 nm gold nanoparticles [36] or by 
a surface coating created by sputtering [37]. The structural change in the aptamer 
due to binding of the analyte reduces access of [Fe(CN)6] 3−/4− to the gold surface 
[36], which can be measured by EIS. Even in the absence of a redox probe, a good 
EIS signal can be obtained due to a combination of steric hindrance and change in 
electrical conductance around the pores resulting from the structural changes that 
occur in the highly negatively charged aptamers upon binding their targets [37].
2.2 Optical aptasensors
Another type of biosensor that utilizes aptamers as bio-recognition elements is the 
optical sensor, for which fluorescent and colorimetric assays are the two widely used 
formats. In general, fluorescent detection is preferred due to its suitability for real-
time detection and because there are many available labeling options as fluorophores 
and quenchers, which can easily be incorporated during aptamer synthesis.
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To convert aptamers into fluorescent signaling probes, several strategies 
have been developed. A frequently used format places an aptamer sequence in a 
molecular beacon-like, hairpin structure in which ends are labeled either with 
two fluorophores or a fluorophore and a quencher. This system utilizes Förster 
resonance energy transfer (FRET), which relies on the energy transfer between 
donor and acceptor. Upon target binding, the structure is disrupted by separating 
the two ends, thus leading to a fluorescence signal. In this format, the use of organic 
fluorescent dyes or quantum dots (QDs) improved the assay performance and could 
also be used to detect drug delivery in cells. Another format places a fluorophore-
labeled aptamer in a duplex structure with a complementary DNA sequence labeled 
with a quencher. The aptamer target successfully competes with the complementary 
DNA resulting in departure of the complementary strand from the aptamer and an 
accompanying increase in the fluorescence signal [26].
In optical analysis, simultaneous detection of several analytes is readily achieved 
by multiplexing. In one of the earliest examples, fluorescently labeled aptamers 
were immobilized on a glass surface. In this system, detection of thrombin and 
three cancer-biomarker proteins, inosine monophosphate dehydrogenase, vascular 
endothelial growth factor, and basic fibroblast growth factor, was achieved by fluo-
rescence polarization even in the presence of human serum and E. coli cell lysates 
[10]. The use of aptamer-linked beads in a microarray setting brought a further 
sophistication of an “electronic tongue” that consists of a fluid delivery system and 
a fluorescence microscope attached to a digital camera for quantification [10].
Graphene oxide-based aptasensors can also be readily multiplexed [10]. As an 
example, a novel label-free fluorescent approach was constructed for H1N1 detec-
tion based on graphene-oxide and strand displacement reaction, using SYBR Green 
I (SGI) for signal amplification [38]. Another example is an assay for detection 
of the pathogenic bacterium, Pseudomonas aeruginosa. This assay was enabled by 
highly specific aptamers conjugated with photoluminescent carbon dots as the 
fluorescent probe and graphene oxide as the quencher, and it allowed detection 
of as low as 9 CFU mL−1 P. aeruginosa [39]. Electrochemiluminescence is another 
output option for aptasensors [40].
2.3 Microcantilever aptasensors
Incorporating aptamers into microcantilever sensors offers the possibility of 
label-free target detection, low noise, high scalability, and small testing volumes [10]. 
Microcantilever-based sensing has been incorporated into several experimental chemi-
cal and biological sensing systems due to its small size, low cost, low sample volume, 
label-free detection, and ease of integration with microfluidic devices [41]. High-
throughput analysis is achievable via microcantilever arrays for parallel processing, 
although they cannot easily be extensively multiplexed. Microcantilever aptasensors can 
be operated in either static or dynamic mode. In a liquid environment, the static mode 
can be more sensitive compared to the dynamic mode. In the static mode, one side of 
the microcantilever is functionalized with aptamers for analyte detection. Surface stress 
is generated when target analyte adsorbs onto the functionalized surface. The difference 
in surface stress between the top and bottom surface results in microcantilever bend-
ing, which can be upward (positive) or downward (negative) depending on the type 
of molecular interactions involved. Displacement of the beam can be detected by using 
readout techniques such as optical, piezoresistive, and capacitive. The optical tech-
nique is the most popular approach because it has high resolution and linear response 
and produces absolute displacement measurement. Detection of proteins and small 
molecule analytes, with an aptamer-decorated cantilever, can be achieved with many 
sensing means including interferometry [42–44] and piezoresistivity [45, 46]. Further 
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development of microcantilever devices will require solutions to their sensitivity to 
vibration and the limits to which they can be multiplexed.
2.4 Acoustic aptasensors
Early work on acoustic aptasensors included the modification of gold-coated 
quartz crystals with aptamers. Target binding changes the frequency or phase shift 
which can be detected as a change in the input and output light. For example, the 
IgE DNA aptamer on a quartz crystal microbalance (QCM) format provided a 
detection limit of 3.3 ng.cm−2 of IgE [47].
Label-free and real-time quantification of proteins were also measured by the 
propagation of the acoustic wave in a surface acoustic wave (SAW) biosensor, 
which included an array of five sensor elements to detect human α-thrombin 
or HIV-1 Rev peptide. This system had a detection limit of 75 pg.cm−2 for both 
α-thrombin and HIV-1 Rev peptide as analytes [48]. The aptamers demonstrated 
a better linear response, stability, and reusability when compared with antibodies 
specific for IgE.
Surface plasmon resonance (SPR) sensors, similar to QCM and SAW aptasen-
sors, rely on a change in refractive index due to target binding. Quartz crystal 
microbalance and surface plasmon resonance aptasensors for detection of HIV-1 
Tat protein were found to have similar high specificities with the SPR sensor having 
a wider linear range [49]. The SPR aptasensor for retinol binding protein-4 was 
found more sensitive than an ELISA [50]. In developing SPR aptasensors, combined 
approaches resulted in a microfluidic device with interdigitated transducer creating 
high-frequency acoustic waves for target separation [51]. Biotinylated-thrombin 
aptamers were captured by streptavidin-functionalized polystyrene, which was 
pumped in the microchannel after incubating with sample. In the microfluidic 
device, SAW exposure leads to separation of thrombin captured in the polystyrene 
by its aptamer from the nontarget serum proteins.
Gold nanoparticles (AuNPs) have also been utilized in developing SPR aptasen-
sors. A U-shaped fiber-optic SPR biosensor was developed for the rapid detection 
of BPA [52]. Incubation of bare AuNPs with BPA aptamer resulted in AuNPs/ssDNA 
complexes which are stable in high salt. Bisphenol A binding disrupted this com-
plex, which resulted in the aggregation of AuNPs and enhanced refractive index 
of the solution in the fiber-optic SPR sensor. This system had a detection limit of 
3.7 pg.mL−1, and linear range was 0.01–50 ng.mL−1.
Neves et al. generated two sensitive cocaine aptasensors that rely on an electro-
magnetic piezoelectric acoustic sensor (EMPAS) platform as the basis of ultra-high 
frequency with tuned signal-to-noise ratio [53]. The sensing interface consists of a 
S-(11-trichlorosilyl-undecanyl) benzenethiosulfonate (BTS) adlayer-coated quartz 
disc onto which a structure-switching cocaine aptamer was immobilized, completing 
the preparation of the MN4 cocaine aptamer with an apparent Kd of 45 ± 12 μM and 
limit of detection of 0.9 μM. The same group developed an MN6 cocaine aptasensor 
using an EMPAS platform that had apparent Kd of 27 ± 6 and a 0.3 μM detection 
limit [54].
Detection of cells using SPRs has some limitations that have been creatively 
overcome. The first limitation includes nonselective binding that causes the refrac-
tive index changes, which can be circumvented by reference flow cells to offset this 
effect [55]. Second is the sensing range, which is typically around 200 nm com-
pared with cell dimensions that are in the micron range. Using long-range SPR, the 
depth was increased over 800 nm, which increased the sensitivity for cell detection 
[56]. Another drawback is its low-throughput, which has been resolved by SPR 
imaging technology.
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3. Clinical perspective
As discussed throughout this chapter, aptamers can be evolved to have high affinity 
and specificity for a range of target molecules that includes small organics, peptides, 
protein, sugar, viruses, bacteria, parasites, live cell, and tissue (Tables 2 and 3).  
This characteristic paves the way for aptamers to have applications in various disci-
plines including sensing, medicine, pharmacology, and microbiology. Aptamer-based 
sensors have great promise as effective tools in the areas of diagnostics and therapeu-
tics for clinical use [164, 165].
3.1 Clinical diagnostics
In clinical practice, the quantification of single biomarkers is frequently not 
sufficient to support a confident diagnosis. Thus, multiple analyses are required for 
each diagnosis, many of which might rely on antibodies, the current workhorses of 
the diagnostic world. Although many antibodies are highly sensitive and specific for 
their antigen targets, they often suffer from batch-to-batch variation. ELISA assays, 
which are the main diagnostic platform for antibodies, have been improved with 
protocols that increase their efficiency and the specificity of their output. However, 
ELISA assays cannot be readily multiplexed to measure simultaneously the many 
biomarkers required for a confident diagnosis. A strength of aptamer biosensors is 
their ability to be multiplexed. Another strength is the range of technologies that 
can be applied to produce operating aptasensors [166–168]. With these strengths to 
drive it, aptasensor technology is one of the fastest growing biotechnology areas in 
diagnostics with an expectation of reaching about $250 million by 2020 [169, 170].
Aptamers can provide new opportunities for medical diagnostics beyond what 
is available with antibodies [18, 171]. For example, aptamers can be selected against 
non-immunogenic and toxic targets, to which antibodies cannot be elicited. These 
short, single-stranded oligonucleotides can be synthesized via simple chemical 
synthesis, making them easier and less costly to produce than antibodies [172]. 
When synthesized in cells containing DNAs encoding RNA aptamers, they can fold 
appropriately and recognize intracellular targets [173–175].
A limited number of aptasensors are in the pipeline to be used in the areas such 
as biomarker and microorganism detection and cancer clinical testing. The avail-
able aptasensors include (1) OTA-Sense for detection of Ochratoxin A (OTA), a 
toxin produced by fungi [165, 176]; (2) AflaSense for detection of aflatoxins [95, 
177–179]; (3) AptoCyto for flow cytometry applications [165]; (4) AptoPrep as a kit 
including conjugated aptamers specific to CD-31, EGFR, HGFR, and ICAM-2 [165]; 
(5) SOMAscan as a platform with the ability to detect >1300 proteins from small 
volumes [180–184]; (6) an aptamer-based proteomics technology developed by 
Jung et al. for detecting non-small cell lung cancer [165]; and (7) OLIGOBIND for 
measuring the thrombin level in blood [185].
Highly sensitive tests are required to specifically detect cancer cells in body fluids 
over all others. Success in this effort requires the identification of biomarkers that are 
found only on tumor cells. Some aptamers have been identified that might be applied 
to detecting tumor cells in the blood. For example, cancer cells and normal cells 
have been distinguished by using electrochemical sensors, a SERS active bimetallic 
core-satellite nanostructure, porphyrin-based covalent organic framework based 
aptasensor [186], and a deterministic lateral displacement (DLD) pattern-based 
aptamer-tailed octopus chip [187]. Recently, some aptasensors have been tested in 
cancer studies. Prostate-specific antigen (PSA), mucin 1 (MUC1), PDGF-BB, and 
vascular endothelial growth factor (VEGF) are detected as cancer biomarkers in 
cancer cell lines [165, 188].
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Organism Target Aptamer Backbone Binding affinity (Kd) Reference
M. tb Beijing 
strain
ManLAM T9 DNA 668 ± 59 nM [57]
M. tb H37Rv CE protein CE24 DNA 0.375 μM [58]
CE protein CE15 DNA 0.16 μM
M. tb CE protein CSIR 2.11 DNA [59]
MPT64 MPT64-A1 DNA [60, 61]
EsxG protein G43 RNA 8.04 ± 1.90 nM [62]
EsxG protein G78 RNA 78.85 ± 9.40 nM
Whole bacterium MA1 DNA 12.02 nM [63]
Whole bacterium Aptamer 1 DNA 37 ± 4 nM [64]
S. typhimurium Outer membrane 
proteins
Aptamers 33 
and 45
DNA [65, 66]
OmpC protein I-2 RNA 20 nM [67]
Whole bacterium C4 DNA [68]
Whole bacterium ST2P DNA 6.33 ± 0.58 nM [69]
Whole bacterium SAL 26 DNA 123 ± 23 nM [70]
Salmonella 
Paratyphi A
Whole bacterium Apt22 DNA 47 ± 3 nM [71]
S. enteritidis Mixtures of 
10 strains of S. 
enteritidis
S25 RNA [72]
Whole bacterium crn1 DNA 0.971 μM [73]
Whole bacterium crn2 DNA 0.309 μM
S. aureus S. Endotoxin B APTSEB1 DNA [74]
S. Endotoxin C1 C10 DNA 65.14 ± 11.64 nM.L−1 [75]
Alpha toxin R12.06 DNA 93.7 ± 7.0 nM [76]
Peptidoglycan Antibac1 DNA 0.415 ± 0.047 μM [77]
Peptidoglycan Antibac2 DNA 1.261 ± 0.280 μM
Protein A PA#2/8 DNA 172 ± 14 nM for the 
recombinant Protein A 
and 84 ± 5 nM for the 
native Protein A
[78]
Whole bacterium SA20 DNA 70.68 ± 39.22 nM [79, 80]
Whole bacterium SA23 DNA 61.50 ± 22.43 nM
Whole bacterium SA31 DNA 82.86 ± 33.20 nM
Whole bacterium SA34 DNA 72.42 ± 35.23 nM
Whole bacterium SA43 DNA 210.70 ± 135.91 nM
Whole bacterium SA17 DNA 35 nM [81]
Whole bacterium SA61 DNA 129 nM
L. 
monocytogenes
Internalin A A8 DNA [82]
Listeriolysin O LLO-3 DNA [83]
Whole bacterium Lbi-17 DNA [84]
Whole bacterium LMCA2 DNA 2.01x10−12 M [85]
Whole bacterium LMCA26 DNA 1.56x10−10 M
E. coli 0157 LPS E-5, E-11, 
E-12, E-16 
to E-19
DNA [86]
E. coli 0158 Whole bacterium AM-6 DNA 107.6 ± 67.8 pmol [87]
E. coli K88 Whole bacterium Apt B12 DNA 15 ± 4 nM [88]
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Organism Target Aptamer Backbone Binding affinity (Kd) Reference
HIV-1 Tat RNATat RNA 120 ± 13 pM [49, 100, 101]
HCV E2 protein ZE2 DNA 1.05 ± 1 nM [102]
Core protein 9–14 RNA 142 nM [103]
Core protein 9–15 RNA 224 nM
Core protein C4 DNA [104, 105]
Influenza A 
virus (H3N2)
HA(91–261) A22 DNA [106]
HA Clone B RNA 200 pM [107]
Whole virus P30-10-16 RNA 188 pM [108]
Influenza A 
virus (H5N1)
HA A10 DNA [109]
Influenza A 
virus (H9N2)
HA(101–257) C7 DNA [110]
Influenza A 
virus (H5N1)
HA HAS15–5 RNA [111]
Influenza A 
virus (H1N1)
HA D-26 RNA 67 fM [112]
Influenza A 
virus (H3N2)
HA HA68 DNA 7.1 nM [113]
Influenza A 
virus (H5N1) 
and (H7N7)
HAs from H5N1 
and H7N7
8-3 RNA 170 fM [114]
Influenza A 
virus
HA1 subunit ApI DNA 64.76 ± 18.24 nM [115]
Influenza A 
virus
HA1 subunit ApII DNA 69.06 ± 12.34 nM
Influenza A 
virus
HA1 subunit ApIII DNA 50.32 ± 14.07 nM
Organism Target Aptamer Backbone Binding affinity (Kd) Reference
E. coli KCTC 
2571
Whole bacterium E1 DNA 12.4 nM [35, 89]
Whole bacterium E2 DNA 25.2 nM
Whole bacterium E10 DNA 14.2 nM
Whole bacterium E12 DNA 16.8 nM
E. coli DH5α Whole cell Ec3(31) RNA 225 nM [90]
Whole cell 8.28A DNA 27.4 ± 18.7 nM [91]
M. tb H37Rv Whole bacterium NK2 DNA [92]
ManLAM ZXL1 DNA 436.3 ± 37.84 nM [93]
BCG ManLAM BM2 DNA 8.59 ± 1 .23 nM [94]
M. tb Acetohydroxyacid 
synthase
Mtb-Apt1 DNA 1.06 ± 0.10 μM [95]
Acetohydroxyacid 
synthase
Mtb-Apt6 DNA 0.210 ± 0.05 μM
S. typhi Type IVB pili S-PS8.4 RNA 8.56 nM [96, 97]
S. aureus SEA S3 DNA 36.93 ± 7.29 nM [98]
α-toxin AT-33 DNA [99]
α-toxin AT-36 DNA
Table 2. 
Aptamers selected against bacteria.
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Organism Target Aptamer Backbone Binding affinity (Kd) Reference
Influenza A 
virus (H9N2)
HA A9 DNA 46.23 ± 5.46 nM [116]
Influenza A 
virus (H9N2)
HA B4 DNA 7.38 ± 1.09 nM [117]
Influenza A 
virus (H5N1) 
and (H5N8)
Whole virus IF22 and 
IF23
DNA [118]
HBV Surface antigen HBs-A22 RNA [119]
HPV 16 E7 protein G5α3N.4 RNA 1.9 μM [120]
HIV-1 Gp120 B40 RNA 21 ± 2 nM [121]
Gp120 B40t77 RNA 31 ± 2 nM
Gp120 A-1 RNA 52 nM [122]
Gp120 BclON-
mut
DNA 143 ± 79 nM [123]
Gp120 F-thio-
BclON
DNA 86 ± 17 nM
RT 1.1RNA RNA 5 nM [124]
RT RT1t49 DNA 1 nM [125]
RT 4.20 DNA 180 ± 70 pM [126]
RT R12–2 DNA 70 nM [127]
RT 37NT DNA 660 pM [128]
RT FA1 FANA 
aptamer
Low pM range [129]
5’-UTR of 
HIV-1 genome
RNApt16 RNA 280 ± 60 nM [130]
TAR RNA 
element
IV04 DNA 20 nM [131]
Integrase T30695 DNA 0.5 ± 0.2 μM [132, 133]
Integrase 93del DNA [56, 134, 135]
Nucleocapsid 
protein
8–6 RNA 1.4x10−9 M [136]
Gag protein DP6–22 RNA 100 ± 3.4 nM [137]
Rev protein RBE(apt) RNA [138]
Integrase S3R3 RNA 47 ± 3 nM [139]
HCV NS3 protein G6–16 RNA 238 nM [140]
Truncated 
protease 
domain of NS3 
protein
G9-I RNA 10 nM [141]
Helicase 
domain of NS3
G5 RNA 25 nM [142]
IRES domains 
III-IV
3–07 RNA 9 nM [143]
IRES AP50 RNA 5 nM [144, 145]
IRES domain 
IIIf and IV
HH-11 RNA [146]
NS5B 27v DNA 132.3 ± 20 nM [147, 148]
NS5B r10/43 RNA 1.3 ± 0.3 nM [149]
NS5B r10/47 RNA 23.5 ± 6.7 nM
NS5B R-F t2 RNA 2.62 ± 0.90 nM [85, 150]
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Many conventional diagnostic technologies for detecting virus and bacteria, 
including serologic-, nucleic acid-, and culture-based tests, are either time-
consuming or expensive on account of the need for sophisticated equipment [188]. 
For example, the gold standard for laboratory diagnosis of acute viral infections is 
isolation and characterization of the virus or bacterium. Isolation and long replica-
tion times for some viruses and bacterial strains can delay confirmation of the 
initial diagnosis for more than a week. The most commonly used alternative method 
is the ELISA. However, cross-reactive antibodies against viruses, particularly when 
they are part of the same virus family, may confound the results of serologic tests 
and may lead to misinterpretation during the epidemiologic assessment in regions 
of the world where they are co-endemic [189]. For instance, among the flaviviruses, 
serological cross-reactivity between Zika virus and dengue virus confounds diag-
nosis of Zika virus infections in pregnant woman in regions where Dengue virus is 
also endemic [190]. Additionally, ELISA-detecting antibodies (IgG and IgM) that 
were produced against the virus do not identify the active infection or the virus 
particles. Because they can interact with different regions of the protein compared 
with antibodies, aptamers might be capable of distinguishing viruses that cannot be 
distinguished serologically [162]. Aptamers that have been reported to specifically 
bind flaviviruses and their protein products including Ebola [162], Zika [163], and 
dengue virus [160] should be tested for their abilities to distinguish these viruses.
The abilities to detect, identify, and quantify microbes and viruses and to 
identify virally infected cells are essential for their early diagnosis. An increas-
ing number of aptamers have been isolated that bind specific microbes such as 
Escherichia coli, Bacillus thuringiensis, Campylobacter jejuni, and Campylobacter coli 
[191], various salmonella species, including S. enteritidis [72] and S. enterica [65], 
and staphylococcus species including S. aureus [79], S. typhimurium [67], and S. 
Organism Target Aptamer Backbone Binding affinity (Kd) Reference
Influenza A 
virus (H5N2)
Glycosylated 
HA
HA12–16 RNA [151]
Influenza A 
virus (H1N1, 
H5N1, H7N7 
and H7N9)
Residues in the 
N-terminal 
of the PAN of 
the influenza 
A virus 
polymerase
PAN-2 DNA 247 ± 11 nM [152]
HBV Truncated P 
protein
S9 RNA [153]
Core protein Apt.No.28 DNA [154]
Capsid AO-01 DNA 180 ± 82 nM [155]
HPV 16 E7 protein A2 RNA 107 nM [156, 157]
E6 protein F2 RNA [158]
SARS-CoV Helicase NG8 DNA 5 nM [159]
DENV-2 Envelope 
protein domain 
III
S15 DNA 200 nM [160]
RABV Glycoprotein GE54 DNA 307 nM [161]
EBOV EBOV sGP 39SGP1A RNA 27 nM [162]
Zika NS1 protein Clone 2 DNA 24 pM [163]
NS1 protein Clone 10 DNA 134 nM
Table 3. 
Aptamers selected against viruses.
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enteritidis [192] (Table 2). In addition to the aptamers recognizing flaviviruses 
discussed in the previous paragraph, there are also aptamers that bind HIV-1 and 
hepatitis C virus (HCV) [188], among others (Table 3).
Aptasensors that have been developed using a number of the aptamers just 
mentioned hold the promise of prompt management of infections with a decreasing 
incidence of morbidity. Another possible application of aptasensors is in vaccine 
development. The costs and extended time associated with the assessment of vaccine 
concentrations by ELISA might be overcome by the application of aptasensors [193].
3.2 Future directions in clinics
Application of aptamer technology in the clinic has the potential of solving some 
stubborn diagnostic problems. Here we discuss some examples.
Tuberculosis (TB) is caused by Mycobacterium tuberculosis and is one of the top 
ten causes of death worldwide [194]. The incidence of childhood TB is reported as a 
half a million cases with 74,000 deaths annually by the World Health Organization 
[195]. The most commonly used diagnostic tool for tuberculosis is the TB skin test. 
However, a false-positive test result in people vaccinated with the bacillus Calmette-
Guerin (BCG) vaccine can be a confounding factor for diagnosis. Thus, the distinc-
tion of infection from disease, particularly in children, is still unclear. Additionally, 
microbiologic confirmation of bacteria in body fluids in childhood is difficult 
because of the poor bacillary count [195–197].
Cytomegalovirus (CMV) causes life-threatening infections in patients 
with solid organ transplantation, hematopoietic stem cell transplantation, and 
AIDS. Cytomegalovirus causes acute and latent infections and reactivates in 
immunosuppressed patients. Isolation and infection control procedures as well as 
proper management of VHFs commonly depend on an accurate diagnosis [198]. 
Current diagnostic tests targeting CMV DNA and CMV antigens are insufficient for 
discriminating acute and latent infections and detecting organ involvement. As a 
result, the results of these tests are frequently misinterpreted [199–201]. Viral hem-
orrhagic fevers (VHFs) are caused by a couple of viruses including Arenaviridae, 
Bunyaviridae, Filoviridae, and Flaviviridae. Fulminant and fatal disease processes 
are the common features of the VHFs and diagnosing and distinguishing of VHF 
from other tropical diseases may be problematic because of the indiscriminatory 
symptoms [202].
An accurate and reliable diagnosis of these and other infections will provide for 
appropriate management and will decrease morbidity and mortality. Thus, devel-
opment of fast microorganism-focused tests will provide rapid accurate diagnosis 
of infection and organ involvements. It seems inevitable that, in the near future, 
many aptamer-based methods/tools will provide for early diagnosis that will enable 
rapid initiation of optimal treatment regimens for viral and bacterial diseases.
4. Future perspective
First identified in 1890 [203], antibodies and their means of interaction with 
their antigens were already being extensively studied in the early twentieth cen-
tury, and their structures were reported in the 1960s by Gerald Edelman [204]. 
Continuing studies of antibodies and the means of eliciting them have resulted in 
a detailed understanding of how they interact with their antigens. This knowledge 
combined with an expansive array of available antibodies motivates scientists to 
incorporate them into new diagnostic tools. Thus, antibody use dominates the 
45 billion dollars global diagnostics market.
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The more recently discovered aptamers are generally compared with anti-
bodies due to their functional similarity. Since the discovery of aptamers in the 
1990s, over a thousand studies have been conducted on applications of aptamers 
for diagnostics. Aptamers that specifically target biomarkers and bacterial or 
viral virulence factors such as surface glycoproteins or secreted proteins have 
been generated. These studies have demonstrated the range of targets that can be 
recognized by aptamers and the number of sensor platforms into which aptam-
ers can be incorporated, many of which have been discussed in this chapter. 
However, the more structurally flexible aptamers are not as readily plugged into 
standard diagnostic assays as antibodies. In this burgeoning and yet immature 
field of aptasensors, there is still much to be learned about how to control 
aptamer behavior.
More systematic studies are needed to optimize selection methods, and more 
aptamers need to be characterized structurally. The biological matrix in which the 
analyte will be measured in the final application platform should be considered at 
the beginning of the selection so as to use buffer and ionic compositions during 
SELEX that resemble the target matrix. Maturation of aptamers to increase specific-
ity for their target analyte in the appropriate matrix and for effective performance 
in the chosen reporter platform is also extremely important.
Aptamers offer the allure of easier production, ease of chemical modifica-
tion, smaller size, reusability, stability even at high temperatures, low cost, and 
a long shelf life. A variety of chemical modifications further enhance aptamer 
stability. A significant advantage over antibody-based assays is that aptamers 
can be reused for many cycles without losing potency with the analyte being 
removed between each cycle by heating or other means. These features hold 
promise for the continued incorporation of aptamers into various sensor plat-
forms and for the further development and eventual commercial application of 
aptasensors for diagnostics.
Acknowledgements
Authors are thankful to the administrative staff members at IntechOpen for 
their invaluable help.
Conflict of interest
MNH is the owner of Aptalogic Inc. located in Ames, IA, USA.
17
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
Aptamers for Diagnostics with Applications for Infectious Diseases
DOI: http://dx.doi.org/10.5772/intechopen.84867
Author details
Muslum Ilgu1*, Rezzan Fazlioglu1, Meric Ozturk1, Yasemin Ozsurekci2  
and Marit Nilsen-Hamilton3
1 Department of Biological Sciences, Middle East Technical University, Ankara, 
Turkey
2 Department of Pediatric Infectious Diseases, Hacettepe University, Ankara, 
Turkey
3 Roy J. Carver Department of Biochemistry, Biophysics and Molecular Biology, 
Iowa State University, Ames, IA, USA
*Address all correspondence to: ilgu@metu.edu.tr
18
Recent Advances in Analytical Chemistry
References
[1] Dahm R. Friedrich Miescher and 
the discovery of DNA. Developmental 
Biology. 2005;278(2):274-288. DOI: 
10.1016/j.ydbio.2004.11.028
[2] Lipfert J, Doniach S, Das R, 
Herschlag D. Understanding nucleic 
acid-ion interactions. Annual Review 
of Biochemistry. 2014;83:813-841. DOI: 
10.1146/annurev-biochem-060409-092720
[3] Song KM, Lee S, Ban C. Aptamers 
and their biological applications. 
Sensors. 2012;12(1):612-631. DOI: 
10.3390/s120100612
[4] Tuerk C, Gold L. Systematic evolution 
of ligands by exponential enrichment: 
RNA ligands to bacteriophage T4 DNA 
polymerase. Science. 1990;249(4968): 
505-510. DOI: 10.1126/science.2200121
[5] Ellington AD, Szostak JW. In vitro 
selection of RNA molecules that bind 
specific ligands. Nature. 1990;346: 
818-822. DOI: 10.1038/346818a0
[6] Robertson DL, Joyce GF. Selection 
in vitro of an RNA enzyme that 
specifically cleaves single-stranded 
DNA. Nature. 1990;344(6265):467-468. 
DOI: 10.1038/344467a0
[7] Hoinka J, Zotenko E, Friedman A, 
Sauna ZE, Przytycka TM. Identification 
of sequence-structure RNA binding 
motifs for SELEX-derived aptamers. 
Bioinformatics. 2012;28(12):i215-223. 
DOI: 10.1093/bioinformatics/bts210
[8] Hoinka J, Berezhnoy A, 
Sauna ZE, Gilboa E, Przytycka 
TM. AptaCluster—A method to 
cluster HT-SELEX aptamer pools 
and lessons from its application. 
Lecture Notes in Computer Science. 
2014;8394(LNBI):115-128. DOI: 
10.1007/978-3-319-05269-4_9
[9] Tombelli S, Minunni M, Mascini M.  
Analytical applications of aptamers. 
Biosensors & Bioelectronics. 
2005;20(12):2424-2434. DOI: 10.1016/j.
bios.2004.11.006
[10] Ilgu M, Nilsen-Hamilton M.  
Aptamers in analytics. The Analyst. 
2016;141(5):1551-1568. DOI: 10.1039/
c5an01824b
[11] Yu Q , Dai Z, Wu W, Zhu H, Ji L.  
Effects of different buffers on the 
construction of aptamer sensors. IOP 
Conference Series: Materials Science 
and Engineering. 2017;274(1):012117. 
DOI: 10.1088/1757-899X/274/1/012117
[12] Bruno JG, Sivils JC. Studies of 
DNA aptamer oligreen and picogreen 
fluorescence interactions in buffer 
and serum. Journal of Fluorescence. 
2016;26(4):1479-1487. DOI: 10.1007/
s10895-016-1840-1
[13] Baaske P, Wienken CJ, Reineck P,  
Duhr S, Braun D. Optical 
thermophoresis for quantifying the 
buffer dependence of aptamer binding. 
Angewandte Chemie International 
Edition. 2010;49(12):2238-2241. DOI: 
10.1002/anie.200903998
[14] Radom F, Jurek PM, Mazurek MP, 
Otlewski J, Jeleń F. Aptamers: Molecules 
of great potential. Biotechnology 
Advances. 2013;31(8):1260-1274. DOI: 
10.1016/j.biotechadv.2013.04.007
[15] Parisien M, Major F. The MC-Fold 
and MC-Sym pipeline infers RNA 
structure from sequence data. Nature. 
2008;452(7183):51-55. DOI: 10.1038/
nature06684
[16] Lu XJ, Bussemaker HJ, Olson WK.  
DSSR: An integrated software tool 
for dissecting the spatial structure 
of RNA. Nucleic Acids Research. 
2015;43(21):e142. DOI: 10.1093/nar/gkv716
[17] Chojnowski G, Waleń T, Bujnicki JM.  
RNA bricks—A database of RNA 3D 
19
Aptamers for Diagnostics with Applications for Infectious Diseases
DOI: http://dx.doi.org/10.5772/intechopen.84867
motifs and their interactions. Nucleic 
Acids Research. 2014;42(Database issue): 
D123-D131. DOI: 10.1093/nar/gkt1084
[18] Banerjee J, Nilsen-Hamilton M.  
Aptamers: Multifunctional molecules 
for biomedical research. Journal of 
Molecular Medicine. 2013;91(12):1333-
1342. DOI: 10.1007/s00109-013-1085-2
[19] Zhou G, Latchoumanin O, Bagdesar M, 
Hebbard L, Duan W, Liddle C, et al. 
Aptamer-based therapeutic approaches 
to target cancer stem cells. Theranostics. 
2017;7(16):3948-3961. DOI: 10.7150/
thno.20725
[20] Esposito CL, Catuogno S, 
Condorelli G, Ungaro P, De Franciscis V.  
Aptamer chimeras for therapeutic 
delivery: The challenging perspectives. 
Genes (Basel). 2018;9(11):529. DOI: 
10.3390/genes9110529
[21] Ismail SI, Alshaer W. Therapeutic 
aptamers in discovery, preclinical and 
clinical stages. Advanced Drug Delivery 
Reviews. 2018;134:51-64. DOI: 10.1016/j.
addr.2018.08.006
[22] Chen M, Yu Y, Jiang F, Zhou J, Li Y, 
Liang C, et al. Development of cell-
SELEX technology and its application 
in cancer diagnosis and therapy. 
International Journal of Molecular 
Sciences. 2016;17(12):2079. DOI: 
10.3390/ijms17122079
[23] Drolet DW, Moon-McDermott L,  
Romig TS. An enzyme-linked 
oligonucleotide assay. Nature 
Biotechnology. 1996;14(8):1021-1025. 
DOI: 10.1038/nbt0896-1021
[24] Ikebukuro K, Kiyohara C, Sode K.  
Electrochemical detection of protein 
using a double aptamer sandwich. 
Analytical Letters. 2004;37(14):2901-
2909. DOI: 10.1081/AL-200035778
[25] Zhou Y, Yin H, Wang Y, Sui C, Wang M,  
Ai S. Electrochemical aptasensors for 
zeatin detection based on MoS2 nanosheets 
and enzymatic signal amplification. The 
Analyst. 2018:143(21):5185-5190. DOI: 
10.1039/C8AN01356J
[26] Song S, Wang L, Li J, Fan C, Zhao J.  
Aptamer-based biosensors. Trends in 
Analytical Chemistry. 2008;27(2):108-
117. DOI: 10.1016/j.trac.2007.12.004
[27] Odacı-Demirkol D, Güleç K.  
Electrochemical sensing and 
fluorescence imaging of E. coli 
O157:H7 based on aptamer-conjugated 
semiconducting nanoparticles. Süleyman 
Demirel Üniversitesi Fen Bilimleri 
Enstitüsü Dergisi. 2018;22:421-426
[28] Ge L, Wang W, Sun X, Hou T, Li F.  
Affinity-mediated homogeneous 
electrochemical aptasensor on a 
graphene platform for ultrasensitive 
biomolecule detection via exonuclease-
assisted target-analog recycling 
amplification. Analytical Chemistry. 
2016;88(4):2212-2219. DOI: 10.1021/acs.
analchem.5b03844
[29] Lai C, Liu S, Zhang C, Zeng G,  
Huang D, Qin L, et al. An 
electrochemical aptasensor based on 
sulfur-nitrogen Co-doped ordered 
mesoporous carbon and thymine-Hg2+-
thymine mismatch structure for Hg2+ 
detection. ACS Sensors. 2018;3(12):2566-
2573. DOI: 10.1021/acssensors.8b00926
[30] Wang S, Zhang L, Wan S, Cansiz S,  
Cui C, Liu Y, et al. Aptasensor with 
expanded nucleotide using DNA 
nanotetrahedra for electrochemical 
detection of cancerous exosomes. ACS 
Nano. 2017;11(4):3943-3949. DOI: 
10.1021/acsnano.7b00373
[31] Qiu H, Sun Y, Huang X, Qu Y. A 
sensitive nanoporous gold-based 
electrochemical aptasensor for 
thrombin detection. Colloids Surfaces B 
Biointerfaces. 2010;79(1):304-308. DOI: 
10.1016/j.colsurfb.2010.04.017
[32] Kashefi-Kheyrabadi L, Mehrgardi MA.  
Aptamer-based electrochemical 
Recent Advances in Analytical Chemistry
20
biosensor for detection of adenosine 
triphosphate using a nanoporous 
gold platform. Bioelectrochemistry. 
2013;94:47-52. DOI: 10.1016/j.
bioelechem.2013.05.005
[33] Zhu B, Alsager OA, Kumar S, 
Hodgkiss JM, Travas-Sejdic J. Label-
free electrochemical aptasensor for 
femtomolar detection of 17β-estradiol. 
Biosensors & Bioelectronics. 
2015;70:398-403. DOI: 10.1016/j.
bios.2015.03.050
[34] Yan M, Sun G, Liu F, Lu J, 
Jinghua Yu XS. Investigations on the 
interface of nucleic acid aptamers and 
binding targets. Analytica Chimica 
Acta. 2013;798:33-39. DOI: 10.1039/
C8AN01467A
[35] Guo Y, Wang Y, Liu S, Yu J, Wang H,  
Wang Y, et al. Label-free and highly 
sensitive electrochemical detection of E. 
coli based on rolling circle amplifications 
coupled peroxidase-mimicking 
DNAzyme amplification. Biosensors & 
Bioelectronics. 2016;75:315-319. DOI: 
10.1016/j.bios.2015.08.031
[36] Peinetti AS, Ceretti H, Mizrahi M,  
González GA, Ramírez SA, 
Requejo FG, et al. Confined gold 
nanoparticles enhance the detection 
of small molecules in label-free 
impedance aptasensors. Nanoscale. 
2015;7(17):7763-7769. DOI: 10.1039/
c5nr01429h
[37] Gosai A, Hau Yeah BS, Nilsen-
Hamilton M, Shrotriya P. Label free 
thrombin detection in presence of high 
concentration of albumin using an 
aptamer-functionalized nanoporous 
membrane. Biosensors & Bioelectronics. 
2019;126:88-95. DOI: 10.1016/j.
bios.2018.10.010
[38] Feng X, Liu K, Ning Y, Chen L, 
Deng L. A label-free aptasensor for 
rapid detection of H1N1 virus based on 
graphene oxide and polymerase-aided 
signal amplification. Nanomedicine and 
Nanotechnology. 2015;6(3):288. DOI: 
10.4172/2157-7439.1000288
[39] Sadeghi AS, Ansari N, Ramezani M,  
Abnous K, Mohsenzadeh M, Taghdisi 
SM, et al. Optical and electrochemical 
aptasensors for the detection 
of amphenicols. Biosensors & 
Bioelectronics. 2018;118:137-152. DOI: 
10.1016/j.bios.2018.07.045
[40] Du X, Jiang D, Hao N, Qian J, 
Dai L, Zhou L, et al. Building a three-
dimensional nano-bio interface for 
aptasensing: An analytical methodology 
based on steric hindrance initiated 
signal amplification effect. Analytical 
Chemistry. 2016;88(19):9622-9629. 
DOI: 10.1021/acs.analchem.6b02368
[41] Luka G, Ahmadi A, Najjaran H, 
Alocilja E, Derosa M, Wolthers K, et al. 
Microfluidics integrated biosensors: A 
leading technology towards lab-on-A-
chip and sensing applications. Sensors 
(Basel). 2015;15(12):30011-30031. DOI: 
10.3390/s151229783
[42] Kang K, Sachan A, Nilsen-
Hamilton M, Shrotriya P. Aptamer 
functionalized microcantilever sensors 
for cocaine detection. Langmuir. 
2011;27(23):14696-14702. DOI: 10.1021/
la202067y
[43] Kang K, Nilsen-Hamilton M, 
Shrotriya P. Differential surface stress 
sensor for detection of chemical and 
biological species. Applied Physics 
Letters. 2008;93(14):14-17. DOI: 
10.1063/1.2996411
[44] Zhai L, Wang T, Kang K, Zhao Y, 
Shrotriya P, Nilsen-Hamilton M. An 
RNA aptamer-based microcantilever 
sensor to detect the inflammatory 
marker, mouse lipocalin-2. Analytical 
Chemistry. 2012;84(20):8763-8770. 
DOI: 10.1021/ac3020643
[45] Lim YC, Kouzani AZ, Duan W, Dai XJ, 
Kaynak, A,  Mair D. Design and evaluation 
of a microcantilever aptasensor. In: ISCAS 
21
Aptamers for Diagnostics with Applications for Infectious Diseases
DOI: http://dx.doi.org/10.5772/intechopen.84867
2014: Proceedings of the 2014 IEEE 
International Symposium on Circuits and 
Systems, IEEE, Piscataway, NJ. 2014. pp. 
221-224. DOI: 10.1109/ISCAS.2014.6865105
[46] Zhao Y, Schagerl M, Viechtbauer C, 
Loh KJ. Characterizing the conductivity 
and enhancing the Piezoresistivity of 
carbon nanotube-polymeric thin films. 
Materials (Basel). 2017;10(7):724. DOI: 
10.3390/ma10070724
[47] Liss M, Petersen B, Wolf H, 
Prohaska E. An aptamer-based quartz 
crystal protein biosensor. Analytical 
Chemistry. 2002;74(17):4488-4495. 
DOI: 10.1021/ac011294p
[48] Schlensog MD, Gronewold TMA, 
Tewes M, Famulok M, Quandt E.  
A love-wave biosensor using 
nucleic acids as ligands. Sensors & 
Actuators,B:Chemical. 2004;101(3):308-
315. DOI: 10.1016/j.snb.2004.03.015
[49] Tombelli S, Minunni M, Luzi E, 
Mascini M. Aptamer-based biosensors 
for the detection of HIV-1 Tat protein. 
Bioelectrochemistry. 2005;67(2 
Spec Issue):135-141. DOI: 10.1016/j.
bioelechem.2004.04.011
[50] Wilson R, Cossins A, Nicolau DV, 
Missailidis S. The selection of DNA 
aptamers for two different epitopes 
of thrombin was not due to different 
partitioning methods. Nucleic Acid 
Therapeutics. 2013;23(1):88-92. DOI: 
10.1089/nat.2012.0386
[51] Ahmad Raston NH, Nguyen VT, 
Gu MB. A new lateral flow strip assay 
(LFSA) using a pair of aptamers for 
the detection of vaspin. Biosensors & 
Bioelectronics. 2017;93:21-25. DOI: 
10.1016/j.bios.2016.11.061
[52] Luo Z, Zhang J, Wang Y, Chen J, Li Y, 
Duan Y. An aptamer based method 
for small molecules detection through 
monitoring salt-induced AuNPs 
aggregation and surface plasmon 
resonance (SPR) detection. Sensors & 
Actuators, B:Chemical. 2016;236:474-479. 
DOI: 10.1016/j.snb.2016.06.035
[53] Neves MADD, Blaszykowski C, 
Bokhari S, Thompson M. Ultra-high 
frequency piezoelectric aptasensor 
for the label-free detection of 
cocaine. Biosensors & Bioelectronics. 
2015;72:383-392. DOI: 10.1016/j.
bios.2015.05.038
[54] Neves MAD, Blaszykowski C, 
Thompson M. Utilizing a key aptamer 
structure-switching mechanism for 
the ultrahigh frequency detection 
of cocaine. Analytical Chemistry. 
2016;88(6):3098-3106. DOI: 10.1021/
acs.analchem.5b04010
[55] Cai S, Yan J, Xiong H, Liu Y, Peng D,  
Liu Z. Investigations on the interface 
of nucleic acid aptamers and binding 
targets. The Analyst. 2018;143(22):5317-
5338. DOI: 10.1039/c8an01467a
[56] Faure-Perraud A, Métifiot M, 
Reigadas S, Recordon-Pinson P, Parissi V, 
Ventura M, et al. The guanine-quadruplex 
aptamer 93del inhibits HIV-1 replication 
ex vivo by interfering with viral entry, 
reverse transcription and integration. 
Antiviral Therapy. 2011;16(3):383-394. 
DOI: 10.3851/IMP1756
[57] Tang XL, Wu SM, Xie Y, Song N, 
Guan Q , Yuan C, et al. Generation 
and application of ssDNA aptamers 
against glycolipid antigen ManLAM 
of Mycobacterium tuberculosis for TB 
diagnosis. The Journal of Infection. 
2016;72(5):573-586. DOI: 10.1016/j.
jinf.2016.01.014
[58] Tang XL, Zhou YX, Wu SM, Pan Q ,  
Xia B, Zhang XL. CFP10 and ESAT6 
aptamers as effective mycobacterial 
antigen diagnostic reagents. The Journal 
of Infection. 2014;69(6):569-580. DOI: 
10.1016/j.jinf.2014.05.015
[59] Rotherham LS, Maserumule C, 
Dheda K, Theron J, Khati M. Selection 
and application of ssDNA aptamers to 
Recent Advances in Analytical Chemistry
22
detect active TB from sputum samples. 
PLoS One. 2012;7(10):e46862. DOI: 
10.1371/journal.pone.0046862
[60] Qin L, Zheng R, Ma Z, Feng Y, 
Liu Z, Yang H, et al. The selection and 
application of ssDNA aptamers against 
MPT64 protein in Mycobacterium 
tuberculosis. Clinical Chemistry and 
Laboratory Medicine. 2009;47(4):405-
411. DOI: 10.1515/CCLM.2009.097
[61] Zhu C, Liu J, Ling Y, Yang H, Liu 
Z, Zheng R, et al. Evaluation of the 
clinical value of ELISA based on MPT64 
antibody aptamer for serological 
diagnosis of pulmonary tuberculosis. 
BMC Infectious Diseases. 2012;12:96. 
DOI: 10.1186/1471-2334-12-96
[62] Ngubane NAC, Gresh L, Pym A, 
Rubin EJ, Khati M. Selection of RNA 
aptamers against the M. tuberculosis 
EsxG protein using surface plasmon 
resonance-based SELEX. Biochemical 
and Biophysical Research 
Communications. 2014;449(1):114-119. 
DOI: 10.1016/j.bbrc.2014.04.163
[63] Aimaiti R, Qin L, Cao T, Yang H,  
Wang J, Lu J, et al. Identification 
and application of ssDNA aptamers 
against H37Rv in the detection of 
Mycobacterium tuberculosis. Applied 
Microbiology and Biotechnology. 
2015;99(21):9073-9083. DOI: 10.1007/
s00253-015-6815-7
[64] Zhang XQ , Feng Y, Yao QQ , He F.  
Selection of a new Mycobacterium 
tuberculosis H37Rv aptamer and 
its application in the construction 
of a SWCNT/aptamer/Au-IDE 
MSPQC H37Rv sensor. Biosensors & 
Bioelectronics. 2017;98:261-266. DOI: 
10.1016/j.bios.2017.05.043
[65] Joshi R, Janagama H, Dwivedi HP,  
Senthil Kumar TMA, Jaykus 
LA, Schefers J, et al. Selection, 
characterization, and application 
of DNA aptamers for the capture 
and detection of Salmonella enterica 
serovars. Molecular and Cellular Probes. 
2009;23(1):20-28. DOI: 10.1016/j.
mcp.2008.10.006
[66] Ma X, Jiang Y, Jia F, Yu Y, Chen J,  
Wang Z. An aptamer-based 
electrochemical biosensor for the 
detection of Salmonella. Journal 
of Microbiological Methods. 
2014;98(1):94-98. DOI: 10.1016/j.
mimet.2014.01.003
[67] Han SR, Lee SW. In vitro selection 
of RNA aptamer specific to Salmonella 
Typhimurium. Journal of Microbiology 
and Biotechnology. 2013;23(6):878-884. 
DOI: 10.4014/jmb.1212.12033
[68] Moon J, Kim G, Lee S, Park S.  
Identification of Salmonella 
typhimurium-specific DNA aptamers 
developed using whole-cell SELEX and 
FACS analysis. Journal of Microbiological 
Methods. 2013;95(2):162-166. DOI: 
10.1016/j.mimet.2013.08.005
[69] Duan N, Wu S, Chen X, Huang Y,  
Xia Y, Ma X, et al. Selection and 
characterization of aptamers against 
Salmonella typhimurium using whole-
bacterium systemic evolution of ligands 
by exponential enrichment (SELEX). 
Journal of Agricultural and Food 
Chemistry. 2013;61(13):3229-3234. DOI: 
10.1021/jf400767d
[70] Lavu PSR, Mondal B, Ramlal S, 
Murali HS, Batra HV. Selection and 
characterization of aptamers using 
a modified whole cell bacterium 
SELEX for the detection of Salmonella 
enterica Serovar Typhimurium. 
ACS Combinatorial Science. 
2016;18(6):292-301. DOI: 10.1021/
acscombsci.5b00123
[71] Yang M, Peng Z, Ning Y, Chen Y, 
Zhou Q , Deng L. Highly specific and 
cost-efficient detection of Salmonella 
paratyphi A combining aptamers 
with single-walled carbon nanotubes. 
23
Aptamers for Diagnostics with Applications for Infectious Diseases
DOI: http://dx.doi.org/10.5772/intechopen.84867
Sensors (Switzerland). 2013;13(5):6865-
6881. DOI: 10.3390/s130506865
[72] Hyeon JY, Chon JW, Choi IS, Park C, 
Kim DE, Seo KH. Development of RNA 
aptamers for detection of Salmonella 
enteritidis. Journal of Microbiological 
Methods. 2012;89(1):79-82. DOI: 
10.1016/j.mimet.2012.01.014
[73] Bayraç C, Eyidoğan F, Avni Öktem H.  
DNA aptamer-based colorimetric detection 
platform for Salmonella enteritidis. 
Biosensors & Bioelectronics. 2017;98:22-28. 
DOI: 10.1016/j.bios.2017.06.029
[74] DeGrasse JA. A single-stranded 
DNA aptamer that selectively binds 
to Staphylococcus aureus enterotoxin 
B. PLoS One. 2012;7(3):e33410. DOI: 
10.1371/journal.pone.0033410
[75] Huang Y, Chen X, Duan N, Wu S, 
Wang Z, Wei X, et al. Selection and 
characterization of DNA aptamers 
against Staphylococcus aureus enterotoxin 
C1. Food Chemistry. 2015;166:623-629. 
DOI: 10.1016/j.foodchem.2014.06.039
[76] Hong KL, Battistella L, Salva AD, 
Williams RM, Sooter LJ. In vitro selection 
of single-stranded DNA molecular 
recognition elements against S. Aureus 
alpha toxin and sensitive detection in 
human serum. International Journal of 
Molecular Sciences. 2015;16(2):2794-
2809. DOI: 10.3390/ijms16022794
[77] Ferreira IM, de Souza Lacerda CM, 
de Faria LS, Corrêa CR, de Andrade 
ASR. Selection of peptidoglycan-
specific aptamers for bacterial cells 
identification. Applied Biochemistry and 
Biotechnology. 2014;174(7):2548-2556. 
DOI: 10.1007/s12010-014-1206-6
[78] Stoltenburg R, Schubert T, Strehlitz B.  
In vitro selection and interaction studies 
of a DNA aptamer targeting Protein 
A. PLoS One. 2015;10(7):e0134403. 
DOI: 10.1371/journal.pone.0134403
[79] Cao X, Li S, Chen L, Ding H, Xu H, 
Huang Y, et al. Combining use of a panel 
of ssDNA aptamers in the detection 
of Staphylococcus aureus. Nucleic Acids 
Research. 2009;37(14):4621-4628. DOI: 
10.1093/nar/gkp489
[80] Borsa BA, Tuna BG, Hernandez FJ, 
Hernandez LI, Bayramoglu G, Arica MY, 
et al. Staphylococcus aureus detection in 
blood samples by silica nanoparticle-
oligonucleotides conjugates. Biosensors 
& Bioelectronics. 2016;86:27-32. DOI: 
10.1016/j.bios.2016.06.023
[81] Chang YC, Yang CY, Sun RL, Cheng YF, 
Kao WC, Yang PC. Rapid single cell 
detection of Staphylococcus aureus by 
aptamer-conjugated gold nanoparticles. 
Scientific Reports. 2013;3:1863. DOI: 
10.1038/srep01863
[82] Ohk SH, Koo OK, Sen T, 
Yamamoto CM, Bhunia AK. Antibody-
aptamer functionalized fibre-optic 
biosensor for specific detection of 
Listeria monocytogenes from food. 
Journal of Applied Microbiology. 
2010;109(3):808-817. DOI: 
10.1111/j.1365-2672.2010.04709.x
[83] Bruno JG, Phillips T, Montez T,  
Garcia A, Sivils JC, Mayo MW, 
et al. Development of a fluorescent 
enzyme-linked DNA aptamer-
magnetic bead sandwich assay and 
portable fluorometer for sensitive and 
rapid listeria detection. Journal of 
Fluorescence. 2015;25(1):173-183. DOI: 
10.1007/s10895-014-1495-8
[84] Suh SH, Jaykus LA. Nucleic acid 
aptamers for capture and detection of 
Listeria spp. Journal of Biotechnology. 
2013;167(4):454-461. DOI: 10.1016/j.
jbiotec.2013.07.027
[85] Lee SH, Ahn JY, Lee KA, Um HJ, 
Sekhon SS, Sun Park T, et al. Analytical 
bioconjugates, aptamers, enable 
specific quantitative detection of 
Listeria monocytogenes. Biosensors & 
Recent Advances in Analytical Chemistry
24
Bioelectronics. 2015;68:272-280. DOI: 
10.1016/j.bios.2015.01.009
[86] Bruno JG, Phillips T, Carrillo MP, 
Crowell R. Plastic-adherent DNA 
aptamer-magnetic bead and quantum 
dot sandwich assay for campylobacter 
detection. Journal of Fluorescence. 
2009;19(3):427-435. DOI: 10.1007/
s10895-008-0429-8
[87] Amraee M, Oloomi M, Yavari A, 
Bouzari S. DNA aptamer identification 
and characterization for E. coli O157 
detection using cell based SELEX method. 
Analytical Biochemistry. 2017;536:36-44. 
DOI: 10.1016/j.ab.2017.08.005
[88] Peng Z, Ling M, Ning Y, Deng L.  
Rapid fluorescent detection of 
Escherichia coli K88 based on DNA 
aptamer library as direct and specific 
reporter combined with immuno-
magnetic separation. Journal of 
Fluorescence. 2014;24(4):1159-1168. 
DOI: 10.1007/s10895-014-1396-x
[89] Kim YS, Song MY, Jurng J, Kim BC.  
Isolation and characterization of DNA 
aptamers against Escherichia coli using 
a bacterial cell-systematic evolution 
of ligands by exponential enrichment 
approach. Analytical Biochemistry. 
2013;436(1):22-28. DOI: 10.1016/j.
ab.2013.01.014
[90] Dua P, Ren S, Lee SW, Kim J, Shin H, 
 Jeong O, et al. Cell-SELEX based 
identification of an RNA aptamer for 
Escherichia coli and Its use in various 
detection formats. Molecules and 
Cells. 2016;39(11):807-813. DOI: 
10.1111/j.1369-7625.2012.00810.x
[91] Renders M, Miller E, Lam CH, Perrin 
DM. Whole cell-SELEX of aptamers 
with a tyrosine-like side chain against 
live bacteria. Organic & Biomolecular 
Chemistry. 2017;15(9):1980-1989. DOI: 
10.1039/C6OB02451C
[92] Chen F, Zhou J, Luo F, Mohammed 
AB, Zhang XL. Aptamer from 
whole-bacterium SELEX as 
new therapeutic reagent against 
virulent Mycobacterium tuberculosis. 
Biochemical and Biophysical Research 
Communications. 2007;357(3):743-748. 
DOI: 10.1016/j.bbrc.2007.04.007
[93] Pan Q , Wang Q , Sun X, Xia X, 
Wu S, Luo F, et al. Aptamer against 
mannose-capped lipoarabinomannan 
inhibits virulent Mycobacterium 
tuberculosis infection in mice and 
rhesus monkeys. Molecular Therapy. 
2014;22(5):940-951. DOI: 10.1038/
mt.2014.31
[94] Sun X, Pan Q , Yuan C, Wang Q ,  
Tang X-L, Ding K, et al. A single 
ssDNA aptamer binding to ManLAM 
of BCG enhances immunoprotective 
effects against tuberculosis. Journal 
of the American Chemical Society. 
2016;138(36):11680-11689. DOI: 
10.1021/jacs.6b05357
[95] Baig IA, Moon JY, Lee SC, Ryoo SW,  
Yoon MY. Development of ssDNA 
aptamers as potent inhibitors 
of Mycobacterium tuberculosis 
acetohydroxyacid synthase. Biochim 
Biophys Acta—Proteins Proteomics. 
2015;1854(10):1338-1350. DOI: 
10.1016/j.bbapap.2015.05.003
[96] Pan Q , Zhang XL, Wu HY, 
He PW, Wang F, Zhang MS, et al. 
Aptamers that preferentially bind 
type IVB pili and inhibit human 
monocytic-cell invasion by Salmonella 
enterica Serovar typhi. Antimicrobial 
Agents and Chemotherapy. 
2005;49(10):4052-4060. DOI: 10.1128/
AAC.49.10.4052-4060.2005
[97] Zelada-Guillen GA, Riu J, 
Düzgün A, Rius FX. Immediate 
detection of living bacteria at ultralow 
concentrations using a carbon nanotube 
based potentiometrie aptasensor. 
Angewandte Chemie International 
Edition. 2009;48(40):7334-7337. DOI: 
10.1002/anie.200902090
25
Aptamers for Diagnostics with Applications for Infectious Diseases
DOI: http://dx.doi.org/10.5772/intechopen.84867
[98] Wang K, Wu D, Chen Z, Zhang X,  
Yang X, Yang CJ, et al. Inhibition 
of the superantigenic activities of 
staphylococcal enterotoxin A by 
an aptamer antagonist. Toxicon. 
2016;119:21-27. DOI: 10.1016/j.
toxicon.2016.05.006
[99] Vivekananda J, Salgado C, 
Millenbaugh NJ. DNA aptamers 
as a novel approach to neutralize 
Staphylococcus aureus α-toxin. 
Biochemical and Biophysical Research 
Communications. 2014;444(3):433-438. 
DOI: 10.1016/j.bbrc.2014.01.076
[100] Yamamoto R, Katahira M, 
Nishikawa S, Baba T, Taira K, Kumar PKR.  
A novel RNA motif that binds efficiently 
and specifically to the Tat protein of 
HIV and inhibits the trans-activation by 
Tat of transcription in vitro and in vivo. 
Genes to Cells. 2000;5(5):371-388. DOI: 
10.1046/j.1365-2443.2000.00330.x
[101] Minunni M, Tombelli S, Gullotto A, 
Luzi E, Mascini M. Development 
of biosensors with aptamers as 
bio-recognition element: The case 
of HIV-1 Tat protein. Biosensors & 
Bioelectronics. 2004;20(6):1149-1156. 
DOI: 10.1016/j.bios.2004.03.037
[102] Chen F, Hu Y, Li D, Chen H, Zhang XL.  
CS-SELEX generates high-affinity 
ssDNA aptamers as molecular probes for 
hepatitis C virus envelope glycoprotein 
E2. PLoS One. 2009;4(12):e8142. DOI: 
10.1371/journal.pone.0008142
[103] Lee S, Kim YS, Jo M, Jin M, ki 
Lee D, Kim S. Chip-based detection 
of hepatitis C virus using RNA 
aptamers that specifically bind to 
HCV core antigen. Biochemical and 
Biophysical Research Communications. 
2007;358(1):47-52. DOI: 10.1016/j.
bbrc.2007.04.057
[104] Shi S, Yu X, Gao Y, Xue B, Wu X, 
Wang X, et al. Inhibition of hepatitis C 
virus production by aptamers against 
the core protein. Journal of Virology. 
2014;88(4):1990-1999. DOI: 10.1128/
JVI.03312-13
[105] Ghanbari K, Roushani M, 
Azadbakht A. Ultra-sensitive aptasensor 
based on a GQD nanocomposite for 
detection of hepatitis C virus core 
antigen. Analytical Biochemistry. 
2017;534:64-69. DOI: 10.1016/j.
ab.2017.07.016
[106] Sung HJ, Kayhan B, Ben-Yedidia T,  
Arnon R. A DNA aptamer prevents 
influenza infection by blocking the 
receptor binding region of the viral 
hemagglutinin. The Journal of Biological 
Chemistry. 2004;279(46):48410-48419. 
DOI: 10.1074/jbc.M409059200
[107] Misono TS, Kumar PKR. Selection 
of RNA aptamers against human 
influenza virus hemagglutinin using 
surface plasmon resonance. Analytical 
Biochemistry. 2005;342(2):312-317. 
DOI: 10.1016/j.ab.2005.04.013
[108] Gopinath SCB, Misono TS, 
Kawasaki K, Mizuno T, Imai M, 
Odagiri T, et al. An RNA aptamer that 
distinguishes between closely related 
human influenza viruses and inhibits 
haemagglutinin-mediated membrane 
fusion. The Journal of General Virology. 
2006;87(3):479-487. DOI: 10.1099/
vir.0.81508-0
[109] Cheng C, Dong J, Yao L, Chen A,  
Jia R, Huan L, et al. Potent inhibition 
of human influenza H5N1 virus 
by oligonucleotides derived by 
SELEX. Biochemical and Biophysical 
Research Communications. 
2008;366(3):670-674. DOI: 10.1016/j.
bbrc.2007.11.183
[110] Choi SK, Lee C, Lee KS, Choe SY, 
Mo IP, Seong RH, et al. DNA aptamers 
against the receptor binding region of 
hemagglutinin prevent avian influenza 
viral infection. Molecules and Cells. 
2011;32(6):527-533. DOI: 10.1007/
s10059-011-0156-x
Recent Advances in Analytical Chemistry
26
[111] Park SY, Kim S, Yoon H, Kim K-B,  
Kalme SS, Oh S, et al. Selection of 
an antiviral RNA aptamer against 
hemagglutinin of the subtype H5 
avian influenza virus. Nucleic Acid 
Therapy (Formerly Oligonucleotides). 
2011;21(6):395-402. DOI: 10.1089/
nat.2011.0321
[112] Gopinath SCB, Kumar PKR.  
Aptamers that bind to the 
hemagglutinin of the recent 
pandemic influenza virus H1N1 and 
efficiently inhibit agglutination. Acta 
Biomaterialia. 2013;9(11):8932-8941. 
DOI: 10.1016/j.actbio.2013.06.016
[113] Wongphatcharachai M, Wang P, 
Enomoto S, Webby RJ, Gramer MR, 
Amonsin A, et al. Neutralizing DNA 
aptamers against swine influenza 
H3N2 viruses. Journal of Clinical 
Microbiology. 2013;51(1):46-54.  
DOI: 10.1128/JCM.02118-12
[114] Suenaga E, Kumar PKR. An 
aptamer that binds efficiently to the 
hemagglutinins of highly pathogenic 
avian influenza viruses (H5N1 and 
H7N7) and inhibits hemagglutinin-
glycan interactions. Acta Biomaterialia. 
2014;10(3):1314-1323. DOI: 10.1016/j.
actbio.2013.12.034
[115] Woo HM, Lee JM, Yim S, Jeong YJ.  
Isolation of single-stranded DNA 
aptamers that distinguish influenza 
virus hemagglutinin subtype H1 from 
H5. PLoS One. 2015;10(4):e0125060. 
DOI: 10.1371/journal.pone.0125060
[116] Zhang Y, Yu Z, Jiang F, Fu P, Shen J, 
Wu W, et al. Two DNA aptamers 
against avian influenza H9N2 virus 
prevent viral infection in cells. PLoS 
One. 2015;10(3):e0123060. DOI: 
10.1371/journal.pone.0123060
[117] Lai HC, Wang CH, Liou TM, 
Bin LG. Influenza A virus-specific 
aptamers screened by using an 
integrated microfluidic system. Lab on 
a Chip. 2014;14(12):2002-2013. DOI: 
10.1016/j.vetpar.2015.05.004
[118] Nguyen VT, Bin SH, Kim BC, Kim SK, 
Song CS, Gu MB. Highly sensitive 
sandwich-type SPR based detection 
of whole H5Nx viruses using a pair of 
aptamers. Biosensors & Bioelectronics. 
2016;86:293-300. DOI: 10.1016/j.
bios.2016.06.064
[119] Liu J, Yang Y, Hu B, Ma ZY, Huang HP, 
 Yu Y, et al. Development of HBsAg-
binding aptamers that bind HepG2.2.15 
cells via HBV surface antigen. Virologica 
Sinica. 2010;25(1):27-35. DOI: 10.1007/
s12250-010-3091-7
[120] Toscano-Garibay JD, Benítez-Hess ML,  
Alvarez-Salas LM. Isolation and 
characterization of an RNA aptamer for 
the HPV-16 E7 oncoprotein. Archives 
of Medical Research. 2011;42(2):88-96. 
DOI: 10.1016/j.arcmed.2011.02.005
[121] Rahim Ruslinda A, Tanabe K, 
Ibori S, Wang X, Kawarada H. Effects 
of diamond-FET-based RNA aptamer 
sensing for detection of real sample 
of HIV-1 Tat protein. Biosensors & 
Bioelectronics. 2013;40(1):277-282. 
DOI: 10.1016/j.bios.2012.07.048
[122] Zhou J, Swiderski P, Li H, Zhang J,  
Neff CP, Akkina R, et al. Selection, 
characterization and application of new 
RNA HIV gp 120 aptamers for facile 
delivery of Dicer substrate siRNAs 
into HIV infected cells. Nucleic Acids 
Research. 2009;37(9):3094-3109. DOI: 
10.1093/nar/gkp185
[123] Prokofjeva M, Tsvetkov V, 
Basmanov D, Varizhuk A, Lagarkova M,  
Smirnov I, et al. Anti-HIV activities 
of intramolecular G4 and Non-G4 
oligonucleotides. Nucleic Acid 
Therapeutics. 2017;27(1):56-66. DOI: 
10.1089/nat.2016.0624
[124] Tuerk C, MacDougal S, Gold L.  
RNA pseudoknots that inhibit human 
immunodeficiency virus type 1 reverse 
transcriptase. Proceedings of the National 
Academy of Sciences of the United States 
of America. 1992;89(15):6988-6992. DOI: 
10.1073/pnas.89.15.6988
27
Aptamers for Diagnostics with Applications for Infectious Diseases
DOI: http://dx.doi.org/10.5772/intechopen.84867
[125] Schneider DJ, Feigon J, Hostomsky Z, 
Gold L. High-affinity ssDNA inhibitors 
of the reverse transcriptase of type 
1 human immunodeficiency virus. 
Biochemistry. 1995;34(29):9599-9610. 
DOI: 10.1021/bi00029a037
[126] Mosing RK, Mendonsa SD, Bowser 
MT. Capillary electrophoresis-SELEX 
selection of aptamers with affinity for 
HIV-1 reverse transcriptase. Analytical 
Chemistry. 2005;77(19):6107-6112. DOI: 
10.1021/ac050836q
[127] Somasunderam A, Ferguson MR, 
Rojo DR, Thiviyanathan V, Li X,  
O’Brien WA, et al. Combinatorial 
selection, inhibition, and antiviral activity 
of DNA thioaptamers targeting the RNase 
H domain of HIV-1 reverse transcriptase. 
Biochemistry. 2005;44(30):10388-10395. 
DOI: 10.1021/bi0507074
[128] DeStefano JJ, Nair GR. Novel aptamer 
inhibitors of human immunodeficiency 
virus reverse transcriptase. 
Oligonucleotides. 2008;18(2):133-144. 
DOI: 10.1089/oli.2008.0103
[129] Ferreira-Bravo IA, Cozens C, 
Holliger P, DeStefano JJ. Selection of 
2′-deoxy-2′-fluoroarabinonucleotide 
(FANA) aptamers that bind HIV-1 
reverse transcriptase with picomolar 
affinity. Nucleic Acids Research. 
2015;43(20):9587-9599. DOI: 10.1093/
nar/gkv1057
[130] Sánchez-Luque FJ, Stich M, 
Manrubia S, Briones C, Berzal-Herranz A.  
Efficient HIV-1 inhibition by a 16 
nt-long RNA aptamer designed by 
combining in vitro selection and in 
silico optimisation strategies. Scientific 
Reports. 2014;1(4):6242. DOI: 10.1038/
srep06242
[131] Boiziau C, Dausse E, Yurchenko L, 
 Toulmé JJ. DNA aptamers selected 
against the HIV-1 trans-activation-
responsive RNA element form 
RNA-DNA kissing complexes. The 
Journal of Biological Chemistry. 
1999;274(18):12730-12737. DOI: 
10.1074/jbc.274.18.12730
[132] Jing N, Hogan ME. Structure-
activity of tetrad-forming 
oligonucleotides as a potent 
anti- HIV therapeutic drug. The 
Journal of Biological Chemistry. 
1998;273(52):34992-34999. DOI: 
10.1074/jbc.273.52.34992
[133] Esposito V, Pirone L, Mayol L, 
Pedone E, Virgilio A, Galeone A.  
Exploring the binding of d(GGGT)4 
to the HIV-1 integrase: An approach 
to investigate G-quadruplex aptamer/
target protein interactions. Biochimie. 
2016;127:19-22. DOI: 10.1016/j.
biochi.2016.04.013
[134] De Soultrait VR, Lozach PY, 
Altmeyer R, Tarrago-Litvak L, Litvak S, 
Andréola ML. DNA aptamers derived 
from HIV-1 RNase H inhibitors are 
strong anti-integrase agents. Journal of 
Molecular Biology. 2002;324(2):195-203. 
DOI: 10.1016/S0022-2836(02)01064-1
[135] Phan AT, Kuryavyi V, Ma J-B, 
Faure A, Andreola M-L, Patel DJ. From 
the cover: An interlocked dimeric 
parallel-stranded DNA quadruplex: 
A potent inhibitor of HIV-1 integrase. 
Proceedings of the National Academy 
of Sciences of the United States of 
America. 2005;102(3):634-639. DOI: 
10.1073/pnas.0406278102
[136] Kim SJ, Kim MY, Jeong S, Kim SJ,  
Lee JH, You JC. Selection and 
stabilization of the RNA aptamers 
against the human immunodeficiency 
virus type-1 nucleocapsid protein. 
Biochemical and Biophysical Research 
Communications. 2002;291(4):925-931. 
DOI: 10.1006/bbrc.2002.6521
[137] Ramalingam D, Duclair S, Datta SAK, 
Ellington A, Rein A, Prasad VR.  
RNA aptamers directed to human 
immunodeficiency virus type 1 gag 
polyprotein bind to the matrix and 
nucleocapsid domains and inhibit 
Recent Advances in Analytical Chemistry
28
virus production. Journal of Virology. 
2011;85(1):305-314. DOI: 10.1128/
JVI.02626-09
[138] Jensen KB, Green L, MacDougal-
Waugh S, Tuerk C. Characterization of 
an in vitro-selected RNA ligand to the 
HIV-1 rev protein. Journal of Molecular 
Biology. 1994;235(1):237-247. DOI: 
10.1016/S0022-2836(05)80030-0
[139] Pang KM, Castanotto D, Li H, 
Scherer L, Rossi JJ. Incorporation 
of aptamers in the terminal loop of 
shRNAs yields an effective and novel 
combinatorial targeting strategy. 
Nucleic Acids Research. 2017;46(1):e6. 
DOI: 10.1093/nar/gkx980
[140] Kumar PKR, Machida K, Urvil PT,  
Kakiuchi N, Vishnuvardhan D, 
Shimotohno K, et al. Isolation of RNA 
aptamers specific to the NS3 protein 
of hepatitis C virus from a pool of 
completely random RNA. Virology. 
1997;237(2):270-282. DOI: 10.1006/
viro.1997.8773
[141] Fukuda K, Vishnuvardhan D, 
Sekiya S, Hwang J, Kakiuchi N, Taira K, 
et al. Isolation and characterization 
of RNA aptamers specific for the 
hepatitis C virus nonstructural protein 
3 protease. European Journal of 
Biochemistry. 2000;267(12):3685-3694. 
DOI: 10.1046/j.1432-1327.2000.01400.x
[142] Nishikawa F, Funaji K, Fukuda K, 
Nishikawa S. In vitro selection of RNA 
aptamers against the HCVNS3 helicase 
domain. Oligonucleotides. 2004;14:114. 
DOI: 10.1089/1545457041526335
[143] Kikuchi K, Umehara T, Fukuda K, 
Kuno A, Hasegawa T, Nishikawa S.  
A hepatitis C virus (HCV) internal 
ribosome entry site (IRES) domain III-IV-
targeted aptamer inhibits translation by 
binding to an apical loop of domain IIId. 
Nucleic Acids Research. 2005;33(2): 
683-692. DOI: 10.1093/nar/gki215
[144] Romero-López C, Barroso-delJesus A,  
Puerta-Fernández E, Berzal-Herranz A.  
Interfering with hepatitis C virus IRES 
activity using RNA molecules identified 
by a novel in vitro selection method. 
Biological Chemistry. 2005;386(2):183-
190. DOI: 10.1515/BC.2005.023
[145] Romero-López C, Díaz-González 
R, Berzal-Herranz A. Inhibition of 
hepatitis C virus internal ribosome 
entry site-mediated translation by 
an RNA targeting the conserved IIIf 
domain. Cellular and Molecular Life 
Sciences. 2007;64(22):2994-3006. 
DOI: 10.1007/s00018-007-7345-y
[146] Romero-López C, Lahlali T, Berzal-
Herranz B, Berzal-Herranz A.  
Development of optimized inhibitor 
RNAs allowing multisite-targeting 
of the HCV genome. Molecules. 
2017;22(5):E861. DOI: 10.3390/
molecules22050861
[147] Bellecave P, Andreola M-L, Ventura 
M, Tarrago-Litvak L, Litvak S, Astier-
Gin T. Selection of DNA aptamers 
that bind the RNA-dependent RNA 
polymerase of hepatitis C virus and 
inhibit viral RNA synthesis in vitro. 
Oligonucleotides. 2003;13(6):455-463. 
DOI: 10.1089/154545703322860771
[148] Bellecave P, Cazenave C, Rumi 
J, Staedel C, Cosnefroy O, Andreola 
ML, et al. Inhibition of hepatitis C 
virus (HCV) RNA polymerase by DNA 
aptamers: Mechanism of inhibition 
of in vitro RNA synthesis and effect 
on HCV-infected cells. Antimicrobial 
Agents and Chemotherapy. 
2008;52(6):2097-2110. DOI: 10.1128/
AAC.01227-07
[149] Jones LA, Clancy LE, Rawlinson WD, 
White PA. High-affinity aptamers 
to subtype 3a hepatitis C virus 
polymerase display genotypic 
specificity. Antimicrobial Agents and 
Chemotherapy. 2006;50(9):3019-3027. 
DOI: 10.1128/AAC.01603-05
[150] Lee CH, Lee YJ, Kim JH, Lim JH, 
Kim J-H, Han W, et al. Inhibition of 
29
Aptamers for Diagnostics with Applications for Infectious Diseases
DOI: http://dx.doi.org/10.5772/intechopen.84867
hepatitis C Virus (HCV) replication 
by specific RNA aptamers against 
HCV NS5B RNA replicase. Journal of 
Virology. 2013;87(12):7064-7074. DOI: 
10.1128/JVI.00405-13
[151] Kwon HM, Lee KH, Han BW, Han 
MR, Kim DH, Kim DE. An RNA aptamer 
that specifically binds to the glycosylated 
hemagglutinin of avian influenza virus 
and suppresses viral infection in cells. 
PLoS One. 2014;9(5):e97574. DOI: 
10.1371/journal.pone.0097574
[152] Yuan S, Zhang N, Singh K, Shuai H, 
Chu H, Zhou J, et al. Cross-protection 
of influenza A virus infection by a DNA 
aptamer targeting the PA endonuclease 
domain. Antimicrobial Agents and 
Chemotherapy. 2015;59(7):4082-4093. 
DOI: 10.1128/AAC.00306-15
[153] Feng H, Beck J, Nassal M, hong Hu K.  
A SELEX-screened aptamer of human 
hepatitis B virus RNA encapsidation 
signal suppresses viral replication. PLoS 
One. 2011;6(11):e27862. DOI: 10.1371/
journal.pone.0027862
[154] Zhang Z, Zhang J, Pei X, Zhang Q ,  
Lu B, Zhang X, et al. An aptamer targets 
HBV core protein and suppresses 
HBV replication in HepG2.2.15 cells. 
International Journal of Molecular 
Medicine. 2014;34(5):1423-1429. DOI: 
10.3892/ijmm.2014.1908
[155] Orabi A, Bieringer M, Geerlof A, 
Bruss V. An aptamer against the matrix 
binding domain on the hepatitis B virus 
capsid impairs virion formation. Journal 
of Virology. 2015;89(18):9281-9287. 
DOI: 10.1128/JVI.00466-15
[156] Nicol C, Bunka DHJ, Blair GE, 
Stonehouse NJ. Effects of single 
nucleotide changes on the binding and 
activity of RNA aptamers to human 
papillomavirus 16 E7 oncoprotein. 
Biochemical and Biophysical Research 
Communications. 2011;405(3):417-421. 
DOI: 10.1016/j.bbrc.2011.01.044
[157] Nicol C, Cesur O, Forrest S, 
Belyaeva TA, Bunka DHJ, Blair GE, 
et al. An RNA aptamer provides a novel 
approach for the induction of apoptosis 
by targeting the HPV16 E7 oncoprotein. 
PLoS One. 2013;8:e64781. DOI: 10.1371/
journal.pone.0064781
[158] Belyaeva T, Nicol C, Cesur Ö, Travé G, 
Blair G, Stonehouse N. An RNA aptamer 
targets the PDZ-binding motif of the 
HPV16 E6 oncoprotein. Cancers (Basel). 
2014;6(3):1553-1569. DOI: 10.3390/
cancers6031553
[159] Shum KT, Tanner JA. Differential 
inhibitory activities and stabilisation 
of DNA aptamers against the SARS 
coronavirus helicase. Chembiochem. 
2008;9(18):3037-3045. DOI: 10.1002/
cbic.200800491
[160] Chen HL, Hsiao WH, Lee 
HC, Wu SC, Cheng JW. Selection 
and characterization of DNA 
aptamers targeting all four serotypes 
of dengue viruses. PLoS One. 
2015;10(6):e0131240. DOI: 10.1371/
journal.pone.0131240
[161] Liang HR, Hu GQ , Li L, Gao YW, 
Yang ST, Xia XZ. Aptamers targeting 
rabies virus-infected cells inhibit street 
rabies virus in vivo. International 
Immunopharmacology. 2014;21(2): 
432-438. DOI: 10.1016/j.
intimp.2014.03.020
[162] Shubham S, Hoinka J, Banerjee S, 
Swanson E, Dillard JA, Lennemann NJ,  
et al. A 2′FY-RNA motif defines an 
aptamer for Ebolavirus secreted  
protein. Science Reports. 
2018;8(1):12373. DOI: 10.1038/
s41598-018-30590-8
[163] Lee KH, Zeng H. Aptamer-
based ELISA assay for highly specific 
and sensitive detection of Zika 
NS1 protein. Analytical Chemistry. 
2017;89(23):12743-12748. DOI: 10.1021/
acs.analchem.7b02862
Recent Advances in Analytical Chemistry
30
[164] Que-Gewirth NS, Sullenger BA.  
Gene therapy progress and prospects: 
RNA aptamers. Gene Therapy. 
2007;14(4):283-291. DOI: 10.1038/
sj.gt.3302900
[165] Kaur H, Bruno JG, Kumar A,  
Sharma TK. Aptamers in the 
therapeutics and diagnostics pipelines. 
Theranostics. 2018;8(15):4016-4032. 
DOI: 10.7150/thno.25958
[166] O’Sullivan CK. Aptasensors—The 
future of biosensing? Analytical and 
Bioanalytical Chemistry. 2002;372:44-48.  
DOI: 10.1007/s00216-001-1189-3
[167] Shamah SM, Healy JM, Cload ST.  
Complex target SELEX. Accounts of 
Chemical Research. 2008;41:130-138. 
DOI: 10.1021/ar700142z
[168] Lim YC, Kouzani AZ, Duan W.  
Aptasensors: A review. Journal of 
Biomedical Nanotechnology. 2010;6(2): 
93-105. DOI: 10.1166/jbn.2010.1103
[169] Dhiman A, Kalra P, Bansal V, Bruno JG, 
Sharma TK. Aptamer-based point-
of-care diagnostic platforms. Sensors 
Actuators, B Chemical. 2017;246: 
535-553. DOI: 10.1016/j.snb.2017.02.060
[170] Sharma TK. The point behind 
translation of aptamers for point of 
care diagnostics. Aptamers (Synthetic 
Antibodies). 2016;3:36-42
[171] Jayasena SD. Aptamers: An 
emerging class of molecules that rival 
antibodies in diagnostics. Clinical 
Chemistry. 1999;45:1628-1650
[172] Zhang P, Zhao N, Zeng Z, Chang CC, 
Zu Y. Combination of an aptamer probe to 
CD4 and antibodies for multicolored cell 
phenotyping. American Journal of Clinical 
Pathology. 2010;134(4):586-593. DOI: 
10.1309/AJCP55KQYWSGZRKC
[173] Abdeevaa IA, Maloshenoka LG, 
Pogorelkoab GV, Mokrykovaa MV, 
Bruskin SA. RNA-aptamers—As targeted 
inhibitors of protein functions in plants. 
Journal of Plant Physiology. 2019;232: 
127-129. DOI: 10.1016/j.jplph.2018.10.026
[174] Konopka K, Lee NS, Rossi J, 
Düzgüneş N. Rev-binding aptamer 
and CMV promoter act as decoys 
to inhibit HIV replication. Gene. 
2000;255(2):235-244. DOI: 10.1016/
S0378-1119(00)00334-6
[175] Chaloin L. Endogenous expression 
of a high-affinity pseudoknot RNA 
aptamer suppresses replication of 
HIV-1. Nucleic Acids Research. 
2002;30(18):4001-4008. DOI: 10.1093/
nar/gkf522
[176] Soh JH, Lin Y, Rana S, Ying JY, 
Stevens MM. Colorimetric detection 
of small molecules in complex 
matrixes via target-mediated growth 
of aptamer-functionalized gold 
nanoparticles. Analytical Chemistry. 
2015;87(15):7644-7652. DOI: 10.1021/
acs.analchem.5b00875
[177] Ruscito A, DeRosa MC. Small-
molecule binding aptamers: Selection 
strategies, characterization, and 
applications. Frontiers in Chemistry. 
2016;4(14):1-14. DOI: 10.3389/
fchem.2016.00014
[178] Liu A, Zhang Y, Chen W, Wang X,  
Chen F. Gold nanoparticle-based 
colorimetric detection of staphylococcal 
enterotoxin B using ssDNA aptamers. 
European Food Research and 
Technology. 2013;237(3):323-329. DOI: 
10.1007/s00217-013-1995-9
[179] Shim WB, Kim MJ, Mun H, Kim MG.  
An aptamer-based dipstick assay for the 
rapid and simple detection of aflatoxin 
B1. Biosensors & Bioelectronics. 
2014;62:288-294. DOI: 10.1016/j.
bios.2014.06.059
[180] Candia J, Cheung F, Kotliarov Y,  
Fantoni G, Sellers B, Griesman T, 
et al. Assessment of variability in the 
SOMAscan assay. Scientific Reports. 
31
Aptamers for Diagnostics with Applications for Infectious Diseases
DOI: http://dx.doi.org/10.5772/intechopen.84867
2017;7(1):14248. DOI: 10.1038/
s41598-017-14755-5
[181] De Groote MA, Nahid P, Jarlsberg L, 
Johnson JL, Weiner M, Muzanyi G,  
et al. Elucidating novel serum biomarkers 
associated with pulmonary tuberculosis 
treatment. PLoS One. 2013;8(4):e61002. 
DOI: 10.1371/journal.pone.0061002
[182] Kraemer S, Vaught JD, Bock C, 
Gold L, Katilius E, Keeney TR, et al. 
From SOMAmer-based biomarker 
discovery to diagnostic and clinical 
applications: A SOMAmer-based, 
streamlined multiplex proteomic assay. 
PLoS One. 2011;6(10):e26332. DOI: 
10.1371/journal.pone.0026332
[183] Lollo B, Steele F, Gold L. Beyond 
antibodies: New affinity reagents to 
unlock the proteome. Proteomics. 
2014;14(6):638-644. DOI: 10.1002/
pmic.201300187
[184] Mehan MR, Ayers D, Thirstrup D, 
Xiong W, Ostroff RM, Brody EN, et al. 
Protein signature of lung cancer tissues. 
PLoS One. 2012;7(4):e35157. DOI: 
10.1371/journal.pone.0035157
[185] Müller J, Friedrich M, Becher 
T, Braunstein J, Kupper T, Berdel P, 
et al. Monitoring of plasma levels of 
activated protein C using a clinically 
applicable oligonucleotide-based 
enzyme capture assay. Journal of 
Thrombosis and Haemostasis. 
2012;10(3):390-398. DOI: 
10.1111/j.1538-7836.2012.04623.x
[186] Yan X, Song Y, Liu J, Zhou N, 
Zhang CL, He L, et al. Two-dimensional 
porphyrin-based covalent organic 
framework: A novel platform for 
sensitive epidermal growth factor 
receptor and living cancer cell 
detection. Biosensors & Bioelectronics. 
2018;5663(18):30944-30948. DOI: 
10.1016/j.bios.2018.11.047
[187] Song Y, Shi Y, Huang M, Wang W,  
Wang Y, Cheng J, et al. Bioinspired 
engineering of multivalent aptamer-
functionalized nanointerface to enhance 
capture and release of circulating tumor 
cells. Angewandte Chemie International 
Edition. 2018;131:1-6. DOI: 1002/
anie.201809337
[188] Hong P, Li W, Li J. Applications 
of aptasensors in clinical diagnostics. 
Sensors. 2012;12(2):1181-1193. DOI: 
10.3390/s120201181
[189] Bhat VG, Chavan P, Ojha S, Nair PK.  
Challenges in the laboratory 
diagnosis and management of dengue 
infections. The Open Microbiology 
Journal. 2015;9:33-37. DOI: 
10.2174/1874285801509010033
[190] Tsai WY, Youn HH, Brites C, 
Tsai JJ, Tyson J, Pedroso C, et al. 
Distinguishing secondary dengue virus 
infection from Zika virus infection 
with previous dengue by a combination 
of 3 simple serological tests. Clinical 
Infectious Diseases. 2017;65(11):1829-
1836. DOI: 10.1093/cid/cix672
[191] Kim YJ, Kim HS, Chon JW, Kim DH, 
Hyeon JY, Seo KH. New colorimetric 
aptasensor for rapid on-site detection of 
Campylobacter jejuni and Campylobacter 
coli in chicken carcass samples. Analytica 
Chimica Acta. 2018;1029:78-85. DOI: 
10.1016/j.aca.2018.04.059
[192] Labib M, Zamay AS, Kolovskaya OS, 
Reshetneva IT, Zamay GS, Kibbee RJ,  
et al. Aptamer-based impedimetric 
sensor for bacterial typing. Analytical 
Chemistry. 2012;84(19):8114-8117. DOI: 
10.1021/ac302217u
[193] Yoon SY, Gee G, Hong KJ, Seo SH.  
Application of aptamers for assessment of 
vaccine efficacy. Clinical and Experimental 
Vaccine Research. 2017;6:160-163. DOI: 
10.7774/cevr.2017.6.2.160
[194] WHO. Tuberculosis. 2018. 
Available from: https://www.who.
int/news-room/fact-sheets/detail/
tuberculosis
Recent Advances in Analytical Chemistry
32
[195] WHO. Global Tuberculosis Report 
2015. DOI: 978-92-4-156450-2
[196] Elhassan MM, Elmekki MA, 
Osman AL, Hamid ME. Challenges in 
diagnosing tuberculosis in children: 
A comparative study from Sudan. 
International Journal of Infectious 
Diseases. 2016;43:25-29. DOI: 10.1016/j.
ijid.2015.12.006
[197] Hilman BC. Pediatric tuberculosis: 
Problems in diagnosis and issues 
in management. The Journal of the 
Louisiana State Medical Society: Official 
organ of the Louisiana State Medical 
Society. 1998;150(12):601-610
[198] Racsa LD, Kraft CS, Olinger GG, 
Hensley LE. Viral hemorrhagic fever 
diagnostics. Clinical Infectious Diseases. 
2016;62:214-219. DOI: 10.1093/cid/
civ792
[199] Miyazaki D, Shimizu D, Shimizu Y,  
Inoue Y, Inoue T, Higaki S, et al. 
Diagnostic efficacy of real-time 
PCR for ocular cytomegalovirus 
infections. Graefe's Archive for Clinical 
and Experimental Ophthalmology. 
2018;256(12):2413-2420. DOI: 10.1007/
s00417-018-4111-9
[200] Nolan N, Halai UA, Regunath H, 
Smith LP, Rojas-Moreno C, Salzer W.  
Primary cytomegalovirus infection 
in immunocompetent adults in the 
United States—A case series. IDCases. 
2017;10:123-126. DOI: 10.1016/j.
idcr.2017.10.008
[201] O’Hara KM, Pontrelli G, Kunstel KL.  
An introduction to gastrointestinal 
tract CMV disease. Journal of the 
Academy of Physician Assistants. 
2017;30:48-52. DOI: 10.1097/01.
JAA.0000524712.40590.76
[202] Marty AM, Jahrling PB, Geisbert TW.  
Viral hemorrhagic fevers. Clinics in 
Laboratory Medicine. 2006;26(2): 
345-386. DOI: 10.1016/j.cll.2006.05.001
[203] Behring K. Ueber das 
Zustandekommen der Diphtherie-
Immunitüt und der Tetanus-Immunitüt 
bei Thieren. Dtsch Medizinische 
Wochenschrift. 1890;16:1113-1114. DOI: 
10.1055/s-0029-1207589
[204] Edelman G. Antibody structure 
and molecular immunology. Annals 
of the New York Academy of Sciences. 
1971;190:5-25
